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ABBREVIATIONS 
 
 
ER                     : Estrogen receptor 
 
 
PR                      : Progesterone receptor 
AR                     :Androgen Receptor. 
RNA                  : Ribonucleic acid 
DNA                  : Deoxy ribonucleic acid 
 
 
HER2                : Human epidermal growth factor receptor 2 
 
 
CK 5/6               : Cytokeratin 5/6 
 
 
ICMR                : Indian council of medical research 
EGFR                : Epidermal growth factor receptor. 
GCDFP              : Gross cystic disease fluid protein. 
DCIS                 : Ductal carcinoma in situ. 
P53                    : Protein 53 
 
 
RT PCR             : Reverse transcriptase polymerase chain 
 
 
Reaction 
 
 
FISH                  : Fluorescent in situ hybridisation 
 
 
BRCA                : Breast cancer antigen 
 
 
LHRH                : Luteinizing hormone releasing hormone
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EXPRESSION OF ANDROGEN RECEPTOR IN PRIMARY BREAST 
CANCER
ABSTRACT
INTRODUCTION: Breast carcinoma has become the most common malignancy in 
the female population and is one of the leading causes of mortality among women in 
India. The most important prognostic factors are the tumor size, histological grade and 
lymphnode stage. The importance of several molecular markers in breast cancer has 
been of considerable interest during recent years not only as prognostic markers but 
also as predictors of response to therapy. Especially, the steroid receptors (estrogen 
receptor (ER), progesterone receptor (PR)), Her2neu, CK5/6 and Ki67 have gained 
increasing interest. The androgen receptor (AR) is one such newly emerging 
biomarker. However the clinical significance of its expression in breast cancer patient 
remains unknown. 
AIMS AND OBJECTIVS: To assess the expression of androgen receptors in primary 
breast carcinomas and to compare the clinicopathological parameters, ER, PR and 
HER2neu expression with AR expression in breast carcinoma. 
MATERIALS AND METHODS: 212 cases were studied for ER, PR and HER2neu 
expression. From them 50 cases were randomly selected and subjected to 
Immunohistochemical detection of Androgen receptor. The difference among 
variables was calculated by Chi square test. 
RESULTS: Of the total 212 cases studied, 51.42% cases were positive for ER, 46.7% 
cases were positive for PR and 26.89% cases positive for HER2neu. Luminal A 
subtype constitutes 12% cases. AR is expressed in 60% cases. AR expression was 
significant in ER and PR positive cases and luminal B subtype. However AR is 
expressed in 31.25% of triple negative cases. 
CONCLUSION : AR is expressed in significant number of breast cancers and 
expression parallels ER and PR expression. It could be an independent prognostic 
marker and additional AR related targeted therapies can be done.
KEY WORDS : Primary breast carcinoma, Androgen receptor, ER, PR, HER2neu 
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INTRODUCTION 
B reast carcinoma constitutes one of the most commonly diagnosed 
cancers worldwide, comprising 16% of the total cases.
 [1]
 In developing 
countries, it is the most common cause for cancer related deaths overtaking 
the cervical cancers with relatively poor survival. Its incidence in India is 25-
30% per 1, 00,000 women and the relative risk is 0.033(1 in 30).
 [2]
 Early 
diagnosis and treatment will certainly reduce the mortality rates. 
Breast cancers exhibit widely varying behavior with regard to the 
likelihood of recurrence, metastasis and response to therapy. 
The most prime prognostic factors are the tumor size, histological 
grade and lymph node stage. The importance of several molecular markers in 
breast cancer has been of considerable interest during recent years not only 
as prognostic markers but also as predictors of response to therapy. 
Especially the steroid receptors (estrogen receptor (ER), progesterone 
receptor (PR)), HER2neu, CK5/6 and Ki67 have gained increasing interest. 
Study of tumor molecular characteristics has led to newer molecular 
classification which helps in enhancing our understanding of both the risk of 
breast cancer recurrence and the response to therapy. 
Immunohistochemically Luminal A constitutes 40-55% of NST which 
are ER positive and HER2neu negative. This phenotype exhibits good 
response to hormonal therapy with little response to conventional 
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chemotherapy in a minority of cases and includes well and moderately 
differentiated carcinoma and is seen in post-menopausal women.  
 Luminal B constitutes 15-20% of NST which expresses ER & HER2neu 
receptors. This phenotype responds well to chemotherapy and indicates 
higher grade and higher proliferative index. It is associated with frequent 
lymph node metastasis. 
 13-25% of NST are basal like which expresses neither ER/PR nor 
HER2neu. 
  The androgen receptor (AR) which is a marker seen in prostate emerges 
as a newer biological marker in breast cancer. However it’s significance of 
expression and its implication in patients with breast tumor remains 
undetected. 
Several studies show that there is significant expression of AR in 
breast tumor cases and proved it as a marker of prognostic significance. Many 
drugs which target AR are under study in breast cancer. 
 In this study of 60 cases which included invasive ductal carcinoma no 
special type (IDC NOS) and its special variants, an attempt has been made to 
evaluate the expression of Androgen receptor by immunohistochemistry. 
Further the histological grade, expression of hormonal receptors like ER, PR 
and other prognostic factors were correlated. 
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AIMS AND OBJECTIVES 
1. To identify the relative frequency and distribution of breast carcinoma in 
the population. 
2. To study the histomorphological features of breast carcinoma including 
grade, lymph node status, lymphovascular invasion, lymphocytic response 
and necrosis. 
3. To assess the expression of ER, PR, HER2neu in invasive breast 
carcinomas. 
4. To assess the expression of Androgen receptor in these cases. 
5. To compare the clinic-pathological parameters and Androgen receptor 
expression in breast carcinoma. 
6.  To assess the correlation between the expression of Estrogen, 
Progesterone Receptors and Androgen Receptor. 
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REVIEW OF LITERATURE 
 Carcinoma breast is the most commonly detected solid epithelial tumor 
in women and it is one of the cancers commonly described in ancient 
literature due to its visibility.
 [3]
 It represents diverse group of tumors that 
vary in clinical behavior and response to treatment. 
 Invasive breast carcinomas are malignant duct epithelial tumors which 
exhibit invasion into adjacent tissues and has increased risk of distant 
metastasis.
 [4] 
 
 The oldest description of breast cancer was given in 1600 BC by Edwin 
Smith Papyrus and first case was documented in 2650 BC by Imhotep. 
[5]
 
 In 1874, the nipple changes that accompany breast cancer was studied 
and described by Paget and it continued to bear his name. 
[6]
 Radical 
mastectomy was first performed by William Stewart Halsted in 1882. X-rays 
were discovered by Wilhelm Conrad Roentgen in 1895 and it forms the basis 
for mammogram and radiotherapy. 
In 1925, the first grading system for breast cancer was evaluated by 
Greenhough. 
[7] 
Grading breast cancer with tubule formation, nuclear 
pleomorphism and hyperchromasia was proposed by Scarff et al in 1928. 
Later in 1957 WHO adapted the numerical scoring system based on tubule 
formation, nuclear pleomorphism and Mitosis 
[8]
 which was proposed by 
Bloom and Richardson. In 1990, Nottingham modified the Bloom and 
Richardson’s grading system. [9] 
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  EPIDEMIOLOGY 
 As per National Cancer Registry Programme ICMR (2009-2011), breast 
cancer is the most common cancer in most cities of India which constitute 
25%-30% of all female cancer and is second most common in rural areas. 
[10]
 
 In India, the crude incidence rate of breast carcinoma is 85/100,000 
women / year.
 [11]
 The death per incident ratio is highest in India, with 50%, 
compared to 30% in China and 18% in the US. 
 It is more common in age group of 50-60 years constituting 69% of 
breast cancer. India is rapidly stepping towards industrialization resulting in 
lifestyle changes. This probably contributes to the increase in breast cancer 
incidence in our country. 
 The annual age-adjusted rate is 30-33 per 1, 00,000 in urban women and 
8.6 per 1, 00,000 in rural women. 
[12]
 
 Histology and molecular analysis showed breast carcinoma is a 
heterogeneous disease composed of morphologically and genetically distinct 
entities with different molecular profile, behavior and response. 
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RISK FACTORS 
 A variety of risk factors are identified based on Epidemiological studies 
combined into BCRAT (Breast Cancer Risk Assessment Tool). 
[13, 14]
 
1. AGE- Peak age group is at 75-80 years in older studies. But current studies 
show a drastic shift in the age group towards younger age group. 
[10]
 
2. HORMONES- The function of Estrogen in Breast is stimulation of cell 
growth and proliferation. It acts as a transcriptional activator by activating via 
Estrogen Receptor. 
[15]
 As per Women’s health initiative trial in 2002, there is 
reduction in incidence of ER positive mammary carcinoma with decrease in 
Hormone replacement therapy. 
[16]
 
3. GENETICS- About 12% of breast cancers is thought to be hereditary 
Mutation in BRCA1 and BRCA2 account for majority of the cancers. 
[17, 18]
 
 BRCA 1 gene is present in chromosome 17q. The product of the gene is 
responsible for DNA repair. Apart from breast cancer, this mutation also has 
increased risk of ovarian cancer and pancreatic cancer. 
[19, 20]
 
 BRCA 2 gene is located in chromosome 13q and this mutation is 
associated with high risk of male breast carcinoma, cancers of Pancreas, 
Prostate and Cutaneous Melanoma. 
[21, 22]
 BRCA 2 gene associated breast 
cancers are poorly differentiated but more often ER positive than BRCA1 
associated cancers. 
[23]
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 Genomicide association studies (GWAS) found out a number of genes 
associated with cancer risk including FGFR2, PTEN, CDH1, TP53 gene. 
[18]
 
 Le Fraumeni syndrome (familial cancer syndrome) is associated with 
P53 tumor suppressor gene mutation. Ataxia telangiectasia patients with 
Cowden syndrome are also associated with increased risk of breast cancer. 
4. SPORADIC BREAST CANCER- Risk factors like Gender, Age at 
Menarche, Menopause, Reproductive history, Breast feeding are based on 
duration of Hormone exposure. Recently, a non-genomic pathway which act 
via G-protein coupled receptor GPR 30 and does not involve ER is identified. 
These result in activation of Metalloproteinase which then act on EGFR and 
results in cell proliferation. 
[24]
 Hence drugs targeted on ER may not be 
enough to inhibit all cancers. 
5. ENVIRONMENTAL FACTORS
 
 
a) Diet: High dietary fat is one of the significant predisposing factors for 
breast cancer. 
b) Alcohol increases the risk of breast cancer. 
c) Radiation: Women treated with mantle radiation for Hodgkins 
lymphoma have 20% to 30% risk of breast carcinoma development. 
   6. OTHER FACTORS 
a) Carcinoma of the contralateral breast (or) endometrium – have increased 
risk of breast cancer.  
b) Breast carcinoma has peculiar association with meningioma. [25] 
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CARCINOGENESIS AND TUMOR PROGRESSION 
 Early lesions like Atypical Ductal Hyperplasia, Atypical lobular 
hyperplasia show increased expression of Hormone receptors and abnormal 
regulation of Proliferation. 
[26, 27]
 Loss of heterozygosity is seen in carcinoma 
in situ lesions. 
 Majority of Carcinomas arise from ER expressing luminal cells. Some 
ER negative tumors arise from myoepithelial cells which are explained by the 
finding that many myoepithelial proteins are shared by triple negative or 
basal like carcinomas. 
[28, 29]
 
Another theory explains that these tumors can arise due to loss of ER 
expression from previously ER positive precursors. 
[26, 30]
 
 
Fig.1: Proposed precursor-carcinoma sequences in breast cancer 
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CLINICAL PRESENTATION 
 50% of breast carcinoma are located in the superior & outer quadrant, 
15% in the superior & inner quadrant, 10% in the inferior & outer quadrant, 
5% in the inferior & inner quadrant, 17% in the central quadrant and 3% are 
diffuse. 
CLINICAL EXAMINATION: 
 Screening for breast abnormalities are done by the triple assessment 
which includes clinical examination, imaging and tissue sampling.  
PALPATION:  
 It remains extremely useful and is the best mode for diagnosis of breast 
carcinoma. 
 
RADIOLOGICAL IMAGING: 
1. Mammogram: 
 The widespread use of mammography brought about a radical change in 
the diagnosis of breast cancer. 
[31, 32]
 
 Mammographic screening was first implemented in the 1980s for 
detecting small non palpable carcinoma that were asymptomatic. 
 With increasing age, the radio dense and fibrous breast tissue of youth 
was replaced by the radioluscent fatty tissue that increases the 
mammographic specificity and sensitivity. 
 The probability of mammographically detected cancerous lesion rises 
from 10% at 40 years to 25% at 35 years of age. 
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 The primary signs of mammographically detected carcinomas include 
density and calcification.  
A. Mammographic Density 
 Mammographic density is produced frequently by invasive carcinoma, 
fibroadenoma or cyst. 
 Most tumors are denser radiologically compared to the adjacent normal 
breast parenchyma. 
 Mammography is valuable for detecting tiny, clinically not palpable 
cancer. 
B. Calcification: 
 Calcification forms in the areas of necrosis, hyalinised stroma or 
secretion. 
 The incidence of calcification in breast carcinoma is 50-60% [33, 34] 
.Whereas the incidence of calcification in benign breast disease is 20%. 
 Hyalinised fibroadenomas, apocrine cysts and sclerosing adenosis are 
associated with benign calcification. 
 Calcification in malignancy are usually tiny, numerous, irregular and 
clustered. 
 DCIS is most frequently detected as a calcification in mammogram. 
They are deposited in linear branching pattern. 
 Small sized Invasive Ductal adenocarcinomas rarely present with 
calcification unaccompanied by mammographic radiodensity. Lymph 
node metastasis is rare in these cases. 
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2. USG: 
 It can distinguish between cystic & solid lesions. 
 It can delineate the borders more precisely in case of solid masses. 
3. MRI:  
 It detects breast carcinomas by uptake of contrast agents owing to 
increased vascularity of the tumor.  
 It is helpful for screening high risk women and those with dense breast. 
 To determine the extent of involvement of chest wall by cancers that are 
locally advanced. 
 For evaluating cases with rupture of breast implants. 
 
TISSUE SAMPLING METHODS 
 Trucut Biopsy 
 Incision Biopsy 
 Excision Biopsy 
 Radical and Modified Radical Mastectomy 
 FNAC 
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CLASSIFICATION OF BREAST CANCERS 
Breast carcinoma is classified clinically based on tumor size, lymph 
node status, local extent and distant spread, morphologically based on 
histological type and grade, At Molecular level, according to hormone 
receptors and HER2neu status. WHO Classification of breast tumor is given 
in Annexure –I. 
MOLECULAR CLASSIFICATION OF BREAST CANCER: 
[35, 36, 37, 38]
 
Luminal A:  
 This phenotype is seen in 40% - 50% of the IDC NOS type cancer. 
 It includes ER positive and HER2neu negative tumor. 
 Most of the tumors are moderately to well differentiated with increased 
expression among post-menopausal female. 
 These tumors are slow growing and respond well to hormonal therapy. 
But response to standard chemotherapy is seen in only minimal number of 
cases. 
Luminal B:  
 This phenotype is seen in 15% - 20% of IDC-NOS type cancer. 
 They are triple positive tumors with expression of ER, PR & HER2neu. 
 They are of higher grade with increased proliferative potential. 
 Increased frequency of nodal metastasis is seen. 
 Responds well to chemotherapy. 
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Normal Breast Like:  
 This phenotype accounts for 6% - 10% of IDC NOS type cancer. 
 This is a minor group consisting of well differentiated ER positive & 
HER2neu negative cancers. They show similar gene expression pattern 
like that of normal breast parenchyma.  
Basal Like:  
 This phenotype accounts for 13% - 25% of IDC NOS type cancer. 
 These tumors are characterized by the absence of PR, ER & HER2neu 
expression with expression of basal myoepithelial markers like P63, P-
Cadherin markers and of progenitor cells / putative stem cells (CK 5/6) 
 This group is referred as “TRIPLE NEGATIVE” Carcinoma. [39, 40] 
 Tumors included in this category are medullary & metaplastic 
carcinomas.  
 Breast carcinomas harboring BRCA1 mutation usually belong to this 
group. 
 They are of higher grade with increased proliferative potential and 
aggressive clinical course. 
 They are frequently associated with visceral and CNS metastasis. 
 Complete response following chemotherapy is seen in only 15-20% of 
cases. 
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HER2neu Positive:  
 This phenotype is seen in 7% - 12% of IDC NOS cancers. 
 It includes carcinomas with HER2neu over expression and ER / PR 
negativity. 
 In 90% of cases, over expression is mainly due to amplification of the 
DNA segment on chromosome 17q21 that harbors the HER2neu gene and 
varying number of adjacent genes. 
 HER2neu assay that include measurement of gene copies number by 
FISH, mRNA level, by gene assay and protein by IHC are all deranged in 
most of these cancers. 
 They are generally poorly differentiated with increased proliferative 
potential & are associated with increased frequency of CNS metastasis. 
 
INFILTRATING DUCTAL CARCINOMA NOS 
 It is the most frequent type constituting 75-80% of breast cancers. 
[41]
 
Grossly, it has irregular infiltrating borders which imparts stellate 
appearance and has firm to hard consistency. It has abundant elastotic 
stroma and small foci of calcification which gives grating sound while 
cutting. 
 Microscopically, it is composed of tubules, solid sheets, nests and 
single cells in varying proportions depending on the degree of 
 
 
15 
 
differentiation. Grading of these tumors is by Nottingham Modification of 
Richardson System. (Annexure III). 
INFILTRATING LOBULAR CARCINOMA 
 This tumor constitutes 10% of all breast carcinomas and it is the 
second commonest type of breast cancer. It has greater incidence of 
bilaterality and multicentricity. Grossly present as a discrete mass or diffuse 
indurated area. 
 Microscopically there is dyscohesive infiltrating tumor cells arranged 
in single file or in loose clusters or sheets. Genetic profile is similar to 
Luminal A. 
[42]
 There is characteristic loss of E-cadherin that function as 
tumor suppressor and biallelic loss of expression of CDH 1. 
[43, 44, 45]
 
 This tumor is positive for HMWkeratin, lack of p53. 
[46]
 To these, p120 
catenin has been recently added, supported by the claim that lobular 
carcinoma shows a characteristic cytoplasmic staining pattern with this 
marker. 
[47]
 Grading is similar to other breast carcinomas. 
[48]
 
MEDULLARY CARCINOMA 
 These tumors have basal like gene expression profile. 
[49]
 Positive for 
CK7 and triple negative. 
[50]
 More common in sixth decade and is associated 
with BRCA1 mutation. 
[51]
 
These are well circumscribed tumors and slow growing thus 
clinically mimicking benign lesion. Grossly, well circumscribed, soft and 
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fleshy. Microscopically, more than 75% of tumor is composed of solid 
sheets of cells with pleomorphic vesicular nucleus and prominent nucleoli 
admixed with lymphoplasmacytic infiltrate most of them being cytotoxic T 
cells. 
[52]
 
The tumor has increased mitosis and has Pushing border due to 
overexpression of E-cadherin and because of this, metastasis is limited. 
[42]
 
There is a scant fibrous stroma with minimal glandular differentiation. All 
Medullary carcinomas are poorly differentiated but has better prognosis 
than Infiltrating Ductal Carcinomas. 
MUCINOUS CARCINOMA 
 These tumors are common in the older age group (seventh decade) and 
has a variety of names like Colloid carcinoma, Mucoid carcinoma and 
Gelatinous carcinoma. Grossly, they are well circumscribed and appear as a 
gelatinous mass held by fibrous septa. 
 Microscopically, clusters of tumor cells float in a pool of mucin. The 
tumor cell clusters may be solid or exhibit acinar or micropapillary 
architecture. 
[53]
 When mucin forms more than 90% of tumor content, it is 
called Pure mucinous carcinoma, Otherwise it is called Mixed mucinous 
carcinoma. 
 The mucin in the tumor is extracellular and acid or neutral type. 
[54]
 
Histochemically, they are O-acylated forms of Sialomucin. 
[55]
 They are 
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strongly positive for MUC2. 
[56]
 These tumor cells are ER, PR positive and 
HER2neu negative. 
[57]
 
APOCRINE CARCINOMA: 
 This is a rare tumor type constituting 1-4% of breast carcinomas. In 
this tumor more than 90% of tumor cells are of apocrine cells. 
[58]
 
 Microscopically, there are two types of apocrine cells. Type A cells 
with abundant acidophilic granular cytoplasm and Type B cells with clear 
foamy cytoplasm. There is glandular differentiation with characteristic 
apocrine snouts. These tumors are positive for Androgen receptor and 
negative for ER, PR and BCl2. 
METAPLASTIC CARCINOMA 
 This is a rare tumor subtype with predominant component of tumor has 
an appearance other than epithelial and glandular type. 
[59, 60] 
 
Microscopically, it is composed of heterogeneous components like Spindle, 
squamous, mesenchymal elements like osseous and chondroid material in 
varying proportions. 
 This category also includes Matrix producing carcinoma in which there 
is overt transition from carcinoma to cartilaginous or osseous matrix without 
spindle transition zone. 
[61, 62]
 It has basal like gene profile with infrequent 
lymph node metastasis. 
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TUBULAR CARCINOMA 
 These tumors are common around 50 years of age. Grossly, they are 
small with ill-defined margin and hard consistency. Microscopically, there 
is irregular and angulated glands arranged haphazardly in a desmoplastic 
stroma. 
Low grade DCIS and Flat epithelial Atypia are considered to be 
precursor lesions for this carcinoma. 
CRIBRIFORM CARCINOMA 
 These are rare tumors in which more than 90% of tumor cells are 
arranged in sieve like cribriform pattern similar to insitu counterpart but 
with stromal invasion. 
INVASIVE PAPILLARY CARCINOMA 
 These tumors constitute less than 1% of breast carcinoma. They are 
circumscribed tumors in which cells arranged in delicate blunt papillae and 
myoepithelial cells are absent. It has better prognosis than conventional IDC 
NOS 
INVASIVE MICROPAPILLARY CARCINOMA 
 This category constitutes less than 2% of breast carcinoma. These 
tumors have pseudopapillary structures without fibrovascular core. These 
are high grade tumors, highly invasive and can have psammoma bodies. 
[63]
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NEUROENDOCRINE CARCINOMA 
 This term indicates invasive tumors that exhibit neuroendocrine 
differentiation. 
[64]
 It includes Carcinoid, Large cell neuroendocrine and 
small cell neuroendocrine carcinoma. Microscopically, solid nests of small 
cells separated by fibrous stroma. 
It can be distinguished from breast carcinoma with focal endocrine 
differentiation by IHC which shows expression of neuroendocrine markers 
in more than 50% of tumor cells. 
[65]
 
INFLAMMATORY CARCINOMA 
 This category has its name because clinically it presents as a red warm 
breast with widespread edema. Pathologically, it presents as undifferentiated 
carcinoma with lymphatic permeation. 
 Skin biopsy demonstrates the presence of dermal lymphatic invasion. It 
is an ominous sign for occult inflammatory carcinoma. 
[66]
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PROGNOSTIC FACTORS 
 Prognostic information is important in counseling patients about the 
likely outcome of the cancer, and appropriate treatment. 
AGE OF THE PATIENT 
 Prognosis is better when the patient is less than 50 years of age. 
Prognosis declines after 50 years of age. 
SIZE 
 Size is an important prognostic factor and studies shows good 
correlation between nodal status and survival rate. 
[67, 68]
 Size is one of the 
two criteria for the definition of minimal breast carcinoma, which includes all 
insitu carcinomas regardless of size and invasive carcinomas of <1cm in 
diameter. 
SITE 
             Tumors located in the medial quadrant were associated with higher 
risk of (50%) relapse and tumor-related death than laterally located tumor. 
[69]
 
CYTOARCHITECTURAL TYPE 
There is no significant difference in prognosis between ordinary 
invasive ductal and lobular carcinoma. 
[70]
 Morphological variants like 
Tubular, Mucinous, Medullary, Papillary, Cribriform, Adenoid cystic 
carcinoma and Secretary Carcinoma have good prognosis. 
[71]
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 Variants like Inflammatory, Metaplastic, Squamous cell carcinoma, 
Neuroendocrine and Signet ring cell carcinoma are aggressive tumors with 
bad prognosis. 
[72]
 
PRESENCE OR ABSENCE OF INVASIVENESS 
In tumors of ductal type that have both in situ & invasive component, 
a relationship exists between the proportion of the invasive component and 
the probability of nodal metastasis. 
The amount of insitu component correlates with the incidence of 
multicentricity and indirectly with the probability of occult invasion.
 [73].
 
In situ ductal malignancies of the comedocarcinoma type can be associated 
with metastases in the absence of detectable invasion. 
TUMOR NECROSIS 
Spontaneous tumor necrosis is associated with an increased nodal 
metastases & reduced survival rates, 
[74] 
particularly if very extensive. 
  
This 
feature is usually associated with tumors of high histologic grade. 
[75] 
TYPE OF MARGINS 
Tumors with infiltrating margins have a worse prognosis than tumors 
with pushing margins. 
[76, 77]
 
MICROSCOPIC GRADE 
 Grading is based on Nottingham Modification of Scarff Bloom 
Richardson system (Annexure III). 
[53]
 Ellis et al established that there is an 
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excellent correlation between this grading system and patient’s survival and 
rate of metastasis. 
[29]
 
SKIN INVASION 
Breast carcinomas with infiltration of the overlying skin are associated 
with decreased survival rate. 
[78]
 
NIPPLE INVASION 
Involvement of nipple by carcinomas is associated with higher 
incidence of axillary metastasis. 
[79] 
BLOOD VESSEL EMBOLI 
This finding shows a high correlation with histological grade, size of 
tumor, type of tumor, lymph node status and Development of distant 
metastasis. Vascular invasion is associated with poor prognosis. 
[80]
 
LYMPHATIC TUMOUR EMBOLI 
Presence of tumor emboli in lymphatic vessels within the breast is 
associated with more risk of tumor recurrence. 
[81, 82]
 
LYMPH NODE STATUS 
 Axillary lymph node involvement is an important prognostic factor in 
patients without distant metastasis. Number of axillary nodes involved, level 
of the node and amount of tumor cells in the node, presence or absence of 
tumor crlls in the efferent blood vessels have important implication in 
patient’s survival. [83] 
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METASTASIS 
Locally advanced disease and presence of distant metastasis have 
poor prognosis. The timing and location of metastasis is also influenced by 
the tumor type. 
[84, 85]
 
BRCA-1 STATUS 
The Breast carcinomas developing in BRCA 1 mutation carriers are 
associated with overall poor survival, if they have not received adjuvant 
ftherapy. 
[86] 
Absent (or) reduced nuclear BRCA 1 expression as measured 
immunohistochemically is associated with several microscopic unfavorable 
features and shorter disease free intervals, whereas cytoplasmic expression of 
this marker seems to be associated with development of tumor recurrence. 
[87] 
  
STAGING (TNM) (Annexure VI) 
PROLIFERATION RATE 
 The proliferation rate is measured by mitotic counts, IHC detection of 
cellular proteins like Cyclins, Ki67, and flow cytometry. High proliferation 
rate is associated with poor prognosis but the response to chemotherapy is 
better. It can also be measured by (SPF) S-Phase fraction and thymidine 
labeling index. Tumors with SPF <5% showed a response rate of 46%, those 
with SPF of 5-10% showed 84% response and those with high SPF >10% 
showed 100% response. 
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OTHER PROGNOSTIC FACTORS 
 Many factors like Tumor necrosis, Lymphocytic infiltration, Skin 
infiltration, association with pregnancy and lactation, 
[88]
 BRCA mutation, 
[89]
 vimentin and keratin expression 
[90]
 also have variable prognostic 
implications in breast cancer. 
HORMONE RECEPTORS 
 Breast cancer cells generally express ER, PR as well as Human 
Epidermal Growth Factor Receptor (HER2neu) for breast cancer formation 
and its progression. 
 IHC was discovered 30 years back which was used to classify breast 
cancers. IHC to detect nuclear hormone receptors is correlated with better 
outcome and predict response to hormonal therapy. 
[91, 92]
 
 Hormone receptor expression was initially measured by Dextran coated 
charcoal and sucrose gradient assay and it was now replaced by IHC and a 
very good correlation was established between these methods. 
[93, 94]
 ER 
positive cancer cells depend on estrogen for their growth and hence 
antiestrogenic agents (eg. Tamoxifen) inhibit cell proliferation. 
[95, 96]
 
 ER and PR are coindependent variables. ER being a better predictor of 
response to hormone therapy than PR. 
[97]
 HER2neu positive tumors have 
worse prognosis in spite of showing good response to Monoclonal antibody 
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Transtuzumab. 
[98]
 It can be measured by IHC or FISH and better correlation 
exists with these methods. 
[99, 100]
 
 Fisher et al proposed that presence of ER is significantly associate with 
high nuclear grade, absence of necrosis, marked tumor elastosis and older 
age group. 
[101]
 
 Shorlie et al and Person et al demonstrated the “Heat maps” generated 
by microarray technique was used to find the expression pattern of 426 
genes. 
[102]
 These leads to sub classification of breast tumors. 
[101]
 IHC has 
become surrogate for DNA microarray gene expression classification. 
[66]
 
 Harvey et al in 1999 suggested cut off values for ER/PR score for 
treatment of advanced stage disease. 
0 score = Endocrine therapy will definitely not work. 
2-3 score = 20% possibility of response to therapy. 
4-6 score = 50% possibility of response to therapy. 
7-8 score = 75% possibility of response to therapy. 
 
SIGNIFICANCE OF HER2NEU IN BREAST CANCER 
 About one fourth of primary or metastatic breast cancers over express 
HER2neu. As a result, some breast cancers that are ER positive also are 
HER2neu positive. 
Recent observations have demonstrated that ER positive, HER2neu 
positive metastatic human breast cancers are less likely to respond to 
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hormone therapy than are cancers that are only ER positive. This is consistent 
with the in vitro observation that MCF cells (ER positive) become resistant to 
tamoxifen after they are transfected with the HER2neu oncogene.  
HER2neu activation can result in an alteration of the ER.  
Treatment of cells that over express HER2neu with Estrogen, 
decreases HER2neu mRNA, as well as down regulating the HER2neu 
product. 
Conversely treatment of ER positive cells with HER2neu ligand leads 
to decreased ER expression. 
This cross link between a polypeptide growth factor receptor – 
activated pathway and a hormone receptor pathway appears to be a 
mechanism by which the cell can become hormone independent. 
TRIPLE NEGATIVE BREAST CANCER 
 The cancer which is negative for Hormone receptors ER and PR and 
HER2neu is called Triple negative Breast cancer. This means that these 
tumor growth is not supported by Estrogen and Progesterone Hormones and 
do not have many HER2neu receptors. So they do not respond to the 
treatment by Tamoxifen nor to therapies that target on HER2neu receptors 
(Tanstuzumab).  
 This category incites an interest to Doctors and Researchers in finding 
therapies that interfere with the growth process of HER2neu receptors. The 
triple negative tumors are generally more aggressive tumors, higher grade 
than other breast carcinomas and express basal like markers like CK5/6, P53. 
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It is more common in younger age group especially before 40yrs of age and 
more common in patients with BRCA1 mutation. 
 Triple negative breast cancers are typically treated with multimodality 
therapy using surgery, Radiotherapy and Chemotherapy. Some research 
showed that Triple negative cancers actually showed a better response to 
Chemotherapy than other breast cancers. 
 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry was first described by Dr. Albert Coons in 
1941. Since then numerous advancements in the technique have been made.  
[103]
 The most commonly used technique is the Peroxidase-antiperoxidase 
immune complex method developed by Sternberger in 1970. The newer 
biotin-avidin immunoenzymatic technique was developed by Heitzman and 
Richards in 1974. 
[104, 105]
 
USES OF IHC IN BREAST PATHOLOGY 
1. The use of Myoepithelial markers to assess stromal invasion. 
2. To differentiate between different types of breast cancer. Eg. E-cadherin 
helps to differentiate between ductal and lobular carcinoma. 
3. To differentiate between precursor lesions and malignancy.                        
Eg. HMWCK helps to distinguish between Usual Ductal Hyperplasia 
and Ductal carcinoma insitu. 
4. To find the site of origin in metastatic cancers. 
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5. To detect sentinel lymphnode metastasis. 
6. Assessment of Estrogen and Progesterone receptor status and HER2neu 
overexpression using specific antibodies to receptor proteins. 
7. Evaluation of Metaplastic carcinoma from mesenchymal lesions. 
ANTIGEN RETRIEVAL 
 Shi et al developed the antigen retrieval technique in 1991 in which 
high temperature was used to bring out the antigenicity of the tissues which 
had been masked by formalin fixation. Antigen retrieval is done either by 
heat induced epitope retrieval or proteolytic epitope retrieval. 
HEAT INDUCED 
 The tissue sections are placed in retrieval solution and subjected to heat 
for varying periods of time. This breakdowns the protein crosslinks and 
retrieves antigenicity. 
[106]
 The heat can be applied using microwave oven, 
pressure cooker, steamer, autoclave or water bath. The commonly used 
retrieval solutions are citrate buffer at PH 6, TRIS EDTA at PH 9, EDTA at 
PH 8. 
PROTEOLYTIC EPITOPE RETRIEVAL
 [107]
 
 Tissue antigenicity can also be restored using proteases like Proteinase 
K, trypsin, Chymotrypsin and pepsin. The main disadvantage here is it alters 
tissue morphology and destroys some epitopes. 
 
 
 
29 
 
TARGET ANTIGEN DETECTION METHODS 
 After retrieval specific antibodies are added which forms Antigen 
antibody complex. This can be visualized by Direct and Indirect methods. 
DIRECT METHOD 
 Her labeled antibodies are used which react with antigens in tissue 
sections. Some of the labels are fluorochrome, horse radish peroxidase and 
alkaline phosphatase. It is simple and rapid but has low sensitivity. 
INDIRECT METHOD 
 Here, in the first step unlabeled primary antibody is added which binds 
with the target antigen. Then in the second step, a labeled secondary 
antibody is added which react with the primary antibody. It is more 
sensitive and it uses only a small number of secondary antibodies. 
[108]
 
ANDROGEN RECEPTOR 
 Androgen receptor belongs to a member of nuclear steroid hormone 
receptor superfamily and it shares many structural, functional and 
topographic similarity to Estrogen and Progesterone receptors. 
[109, 110, 111]
 
AR has an important role in the normal development of Prostate and in the 
pathogenesis of Prostatic carcinoma. It also has a role in breast cell 
differentiation, development and growth. In prostate cancer, AR dependent 
cell cycle progression appears to be a critical regulator in G1-S transition. In 
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breast cancer also similar role has been envisaged. It is considered as a 
newly emerging biomarker in breast carcinoma. 
[112]
 
 Androgen Receptor plays a crucial role in breast homeostasis, 
negatively influences the proliferative effects of Estrogen signaling. It also 
influences the risk of breast cancer by converting into estradiol which acts 
on Estrogen or Androgen receptor in breast. 
 Peters et al assessed status of Androgen receptor in 215 cases of breast 
cancer and found that by binding to a subset of Estrogen responsive 
element. AR can block the target gene that mediates the stimulatory effects 
of 17β estradiol on breast cancer. 
 A cell line model for molecular apocrine subtype MDA-MB-453 
demonstrates a proliferative response to androgen in an ER independent 
manner. 
[113]
 And it can be reversed using antiandrogen Flutamide. 
 The antiandrogen Bicalutamide also inhibits the growth of molecular 
apocrine cell lines in-vitro and in-vivo supporting the fact that antiandrogen 
can be used as a targeted therapy. 
[113, 114,115,116]
 
 Various studies show variable results regarding the significance of AR 
expression in breast cancer. Agarwal et al showed that AR is the most 
frequently detected receptor in breast cancer. 
[117]
 
 Agoff SN et al showed that most breast cancer cells have receptors for 
androgen and it may be found in the absence of ER and PR especially in the 
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absence of ER. 
[118, 119]
 Many studies have shown that AR expression is 
more frequent in Lobular carcinoma, Apocrine carcinoma and Paget’s 
disease of nipple. 
[120, 121, 122]
 
 Literature has shown that DHEA and its sulfate has growth inhibitory 
effects on Estrogen and Progesterone receptor negative breast cancer lines 
that show AR expression. 
[123, 124]
 
 Leo A Neiemeier et al showed AR positivity in 80% of invasive breast 
carcinomas and 95% of ER positive breast carcinomas and 10% of triple 
negative breast carcinomas. 
[125]
 
 Park et al found AR positivity in 58% of breast carcinomas and 35% of 
triple negative breast carcinomas and it is 72.9% higher than those of 
ER.
[126]
 
 Dawn R Cochrane et al indicated AR positivity in 77% of breast 
cancers and 88% of ER positive, 59% of HER2neu positive and 32% of 
triple negative breast cancers. 
[127]
 
 Hu R et al showed that AR is reported in almost 56% of patients with 
ER negative breast carcinomas. 
[128]
 Literaturealso showed that AR can be 
an independent prognostic factor with 61% expression in basal like breast 
cancer which has poor prognosis. 
[121]
 
Dawn R Cochrane et al also showed that AR expression is associated 
with 4 fold increased risk of tamoxifen failure. So AR had an independent 
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effect on risk for failure with hormone therapy. 
[127]
 AR:ER ratio is also an 
independent predictor of disease free survival.   
Mishra et al shows that the breast cancers whish show AR expression 
have prolonged survival and better response to hormonal treatment than AR 
negative cases. 
[130]
 
 Francisco et al did a Meta-analysis of 19 studies and showed that AR 
expression was documented in 60.5% of cases and concluded that ER 
positive tumors are more likely to express AR than ER negative tumors. 
And show improved overall survival.  
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                             MATERIALS AND METHODS 
This study is a descriptive prospective and retrospective study of 
Primary breast carcinomas conducted in the Institute of Pathology, Madras 
Medical College and Rajiv Gandhi Government General hospital, Chennai 
during the period between Jan 2013 to Jun 2015. 
Source of data 
              The invasive ductal carcinoma cases reported in mastectomy 
specimen received in the Institute of Pathology, Madras Medical College 
between Jan 2013 to Jun 2015 from the Department of Surgery, Oncology, 
and Plastic surgery, Government General Hospital. A total of 364 
mastectomy specimens (simple, modified radical or radical mastectomy) 
were received during this period. 
Inclusion criteria: 
 All modified radical mastectomy specimens of breast carcinomas. 
 All invasive breast carcinomas no special type (ductal and lobular), 
medullary, mucinous, papillary, apocrine and metaplastic carcinomas 
irrespective of the age and sex were included for the study. 
Exclusion criteria: 
 All Trucut biopsies. 
 Phylloides tumors. 
 Benign breast lesions. 
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 Tumors with preexisting premalignant conditions. 
 Recurrent tumors. 
METHOD OF DATA COLLECTION 
Of the total 364 cases reported during this study period, ER, PR and 
HER2neu expression was studied for 212 cases. Detailed   history   of   the   
cases   regarding   age,   sex,   menstrual history, side of the breast, type of 
procedure, history of neo adjuvant therapy, details of gross characteristics 
such as tumor size, nodal status details were obtained for those 212 cases 
from surgical pathology records. Formalin fixed tissue were cut, processed 
and paraffin embedded. 
      4μm thick sections of the paraffin tissue blocks were cut and stained 
with eosin and hematoxylin. Slides were collected from slide filing and were  
reviewed  and  graded  using  the  Nottingham  modification of  the Scarff 
Bloom Richardson Grading system (Annexure III) and they were further 
evaluated for the presence of necrosis, lymphocytic response, 
lymphovascular invasion and skin infiltration . 10 cases of each grade from 
Invasive ductal carcinoma NST and 20 cases from special type as 
medullary, metaplastic, mucinous, apocrine, papillary and invasive lobular 
were randomly selected from the total cases and their representative formalin 
fixed paraffin embedded tissue samples were subjected to 
immunohistochemical analysis of Androgen Receptor. Slides were evaluated 
and scoring was given. The results were recorded with photographs. 
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IMMUNOHISTOCHEMICAL EVALUATION 
Immunohistochemical analysis of ER, PR, H2N and AR were done 
in Paraffin embedded tissue samples  using  supersensitive polymer HRP 
system based on non-biotin polymeric technology. 
Table 1: Immunohistochemical markers used in the current study 
Antigen Vendor Clone Dilution Positive 
control 
ER Dako Rabbit 
Monoclonal 
EP1 
Ready to 
Use 
Breast 
PR Dako Mouse 
Monoclonal 
Ready to 
Use 
Breast 
HER2neu Dako Rabbit 
Monoclonal 
SP-3 
Ready to 
Use 
Breast 
    AR PathnSitu Rabbit 
Monoclonal 
Ready to 
Use 
Prostate 
 
       4 μm thick sections from selected formalin fixed paraffin embedded 
tissue samples were transferred onto gelatin coated slides. Heat induced 
antigen retrieval was done using microwave method. The ER and PR 
antigens are bound with mouse monoclonal antibodies (dako) and 
HER2neu(dako) and          AR(PathnSitu) antigens are bound with rabbit 
monoclonal antibody. Later antigen antibody complex are detected by the 
addition of secondary antibody conjugated with horse radish peroxidase-
polymer and Diaminobenzidine substrate. The step by step procedure of 
Immunohistochemistry is given in Annexure IV. 
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INTERPRETATION & SCORING SYSTEM 
 PR and AR 
Hormone receptors like Estrogen and Progesterone receptor, when 
expressed show a nuclear positivity. The number of cells expressing and 
their intensity of staining is scored as two values and a composite score 
based on percentage plus intensity of more than 2 is considered to be 
positive. (Annexure V). 
H2N: 
HER2neu expression is demonstrated in tumor cells as cytoplasmic 
expressing is graded as 1+, 2+ and 3+. (Annexure V) 
 
STATISTICAL ANALYSIS 
 The Statistical analysis for this study was done using the software IBM 
Statistical Package for social science version 21. The correlation between AR 
expression and different clinicopathological parameters like age group, size, 
side, grade, lymphnode status, lymphovascular invasion, lymphocytic 
infiltration, necrosis, skin infiltration, Hormonal receptors like ER, PR and 
HER2neu was made and strength of association was calculated by Pearson 
Chi square test and P value less than 0.05 are considered statistically 
significant. 
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OBSERVATION AND RESULTS 
In the study period of 30 months from Jan 2013 to June 2015, a total 
of 27,576 specimens were received in the Institute of Pathology, Madras 
Medical College for histological examination. 
Total numbers of breast specimens received were 1515 cases, of 
these breast tumors accounted for 1145 cases with a percentage of 4.15% of 
all cases (including both incisional and excisional biopsies). 
The total number of non-neoplastic, benign and malignant cases was 
370, 484 and 661 respectively.  Thus the distribution of non-neoplastic 
breast lesions was 24.42%, benign tumors were 31.95% and of malignant 
tumors were 43.63%. 
Out of a total of 661 breast cancer cases, only 364 cases constituted 
radical mastectomy specimens. 
Table 2: Distribution of breast cases 
 Non neoplastic Benign Malignant 
Breast 370 484 661 
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The age wise distribution of these 212 cases is given below (Table 3 and 
Chart 1) 
Table 3: Age Wise Distribution Of Breast Cancers 
AGE NO OF CASES PERCENTAGE 
21-30 3 1.41% 
31-40 37 17.45% 
41-50 83 39.15% 
51-60 63 29.71% 
61-70 23 10.85% 
MORE THAN 70 3 1.41% 
TOTAL 212 100% 
 
Highest incidence of Breast cancers is found in the age group of 41-50 
years. The youngest age of presentation of breast cancer is at 30 years in 
this study. 
The distribution of histological subtypes of breast carcinoma is 
shown (Table 4, chart 2). 
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                         Chart 1: Age  distribution of Breast cancers 
 
 
 
Table 4: Distributions of Histological Subtypes of Breast Cancers 
HISTOLOGICAL SUBTYPES NO OF CASES PERCENTAGE 
Invasive ductal carcinoma NOS 190 89.62% 
Metaplastic Carcinoma 6 2.83% 
Mucinous Carcinoma 5 2.36% 
Apocrine Carcinoma 4 1.89% 
Invasive Lobular Carcinoma 3 1.42% 
Medullary carcinoma 2 0.94% 
Neuroendocrine carcinoma 1 0.47% 
Invasive Papillary carcinoma 1 0.47% 
Grand Total 212 100.00% 
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 Invasive Ductal carcinoma constitutes the most common carcinoma 
with 89.62% of all cases. 
Chart 2: Distribution of histological type 
 
Table 5: Distribution of side of involvement in Breast 
 
SIDE 
NO OF CASES PERCENTAGE 
 
Left 
100 47.17% 
 
Right 
112 52.83% 
 
Grand Total 
212 100.00% 
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Chart-3: Distribution of side of cancer 
 
100 cases of primary breast carcinoma were reported in left breast and 
112 cases were reported in right Breast. (Table 5 and Chart 3) 
            Table 6: Distribution of size in Invasive Ductal Carcinoma 
SIZE OF TUMOR NO OF CASES PERCENTAGE 
<2cm(T1) 9 4.25% 
2-5cm(T2) 149 70.28% 
>5cm(T3) 54 25.47% 
TOTAL 212 100.00% 
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9 cases (4.25%) had tumor less than 2 cm in size, 149 cases 
(70.28%) were of 2 to 5 cm in size and 54 cases (25.47%) were more than 5 
cm in size. (Table 6 & Chart 4). 
Chart-4: Distribution of size of the tumor 
 
 
Table 7: Distribution of Histological Grade in IDC-NOS Type 
GRADE NO OF CASES PERCENTAGE 
I 38 20.00% 
II 118 62.11% 
III 34 17.89% 
Grand Total 190 100.00% 
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There  were  190  Invasive  ductal  carcinoma  NOS  type  breast 
cancers in the study sample which were graded according to Modified 
Scarff Bloom Richardson grading system out of which 38 cases(20%) were 
in grade I,  118  cases (62.11%) were in grade II  and 34  cases 
(17.89%) were in grade III. (Table 7 & Chart 5) 
 
79 cases (37.26%) had up to 3 nodes with metastatic ductal 
carcinomatous deposit, 41 cases (19.34%) had 4 to 10 involved nodes, 9 
cases (4.2%) had more than 10 involved nodes, while 83 cases (39.15%) 
had no lymph node involvement (Table 8 & Chart 6). 
 
Table 8: Distribution of Lymph Node Metastasis in Breast Cancers 
LYMPH NODE STATUS NO OF CASES PERCENTAGE 
Negative 83 39.15% 
1-3 positive nodes 79 37.26% 
4-10 positive nodes 41 19.34% 
>10 positive nodes 9 4.25% 
Total 212 100.00% 
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Chart-5: Distribution of grade in IDC-NOS 
 
 
                         Chart 6 : Distribution of Nodal Metastasis 
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Table 9: Distribution of lymphovascular invasion 
LYMPHOVASCULAR 
INVASION 
NO OF 
CASES 
PERCENTA
GE 
ABSENT 113 53.30% 
PRESENT 99 46.70% 
TOTAL 212 100.00% 
            
  99 cases (46.70%) had lymphovascular invasion as against 113 cases 
(53.3%) without lymphovascular invasion (Table 9 & Chart 7). 
            17 out of 212 primary breast cancers have skin infiltration 
which constitutes 8.02% (Table 10 & chart 7). 
 
Table 10: Distribution of skin infiltration in Invasive Ductal 
Carcinoma Breast 
SKIN INFILTRATION NO OF CASES PERCENTAGE 
ABSENT 195 91.98% 
PRESENT 17 8.02% 
TOTAL 212 100.00% 
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Chart 7: Distribution of Lymphovascular invasion and Skin 
infiltration 
 
 
Chart 8: Distribution of Lymphocytic infiltration & Necrosis 
 
0
20
40
60
80
100
120
140
160
180
200
SKIN INFILTRATION LYMPHOVASCULAR INVASION
195 
113 
17 
99 
ABSENT PRESENT
0
20
40
60
80
100
120
140
160
LYMPHOCYTIC INFILTRATION NECROSIS
99 
143 
113 
69 
Absent Present
 
 
47 
 
Table 11: Distribution of lymphocytic infiltration in Invasive Ductal 
Carcinoma Breast 
LYMPHOCYTIC 
INFILTRATION 
NO OF CASES PERCENTAGE 
Absent 99 46.70% 
Present 113 53.30% 
Total 212 100.00% 
 
Lymphocytic infiltration is seen in 113 cases which forms 53.3% of all 
cases (Table 11) and 32.55% of the cases had necrosis (Table 12) as shown 
in Chart 8. 
 
Table 12: Distribution of necrosis in Breast Cancer 
NECROSIS NO OF CASES PERCENTAGE 
Absent 143 67.45% 
Present 69 32.55% 
Grand Total 212 100.00% 
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RESULTS OF IMMUNOHISTOCHEMISTRY 
Table 13: Distribution of  Estrogen Receptor expression in Breast 
cancers. 
ER NO OF CASES PERCENTAGE 
NEG 103 48.58% 
POS 109 51.42% 
Grand Total 212 100.00% 
  
IHC scoring of ER and PR done using Alred scoring system based on 
staining intensity and proportion of cells exhibiting positivity shows 103 
cases of ER positivity which forms 51.42% of cases (Table 13) whereas PR 
expression is seen in 99 cases which constitute 46.7% of cases (Table 14, 
chart 9). 
           Table 14: Distribution of Progesterone Receptor Expression in  
                                            Breast cancers.  
PR NO OF CASES PERCENTAGE 
NEG 113 53.30% 
POS 99 46.70% 
Grand Total 212 100.00% 
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Chart 9:  Expression of ER and PR in primary Breast cancers. 
 
                                        Chart -10: Expression of HER2neu 
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156 cases (73.58%) were Positive for HER2neu ( Table 15, chart 10) 
Table 15: Distribution of HER2neu expression in Breast cancers.  
H2N NO OF CASES PERCENTAGE 
NEG 155 73.11% 
POS 57 26.89% 
Grand Total 212 100.00% 
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EXPRESSION OF ANDROGEN RECEPTOR 
In   this   study,   60%   expressed   positive   reaction   for   AR 
(Table 16 & Chart 11) 
Table-16: Distribution of Androgen Receptor expression in Breast 
cancers. 
DISTRIBUTION OF AR NO OF CASES PERCENTAGE 
NEG 20 40% 
POS 30 60% 
Grand Total 50 100% 
 
Chart-11: Expression of AR
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CORRELATION    OF    AR    WITH    OTHER    PROGNOSTIC 
FACTORS 
Table-17: Correlation of Age distribution and Expression of Androgen 
Receptors 
Age 
AR expression 
total P value 
Positive Negative 
21-30 1(50%) 1(50%) 2 
0.260728 
 
31-40 4(66.7%) 2(33.3%) 6 
41-50 6(37.5%) 10(62.5%) 16 
51-60 12(66.7%) 6(33.3%) 18 
61-70 6(85.7%) 1(14.3%) 7 
MORE THAN 70 1(100%) 0(0%) 1 
TOTAL 30 20 50 
 
Expression of Androgen receptor is more in the age group of 61-70 years 
with 85.7% positivity and one case over 70 years is positive for AR. The 
least AR positivity is seen in the age group of 41-50 years with 37.5% of 
cases although it is not significant. (Table 17 & Chart 12). 
 Androgen receptor is seen 100% cases of Apocrine carcinoma, Lobular 
carcinoma and Neuroendocrine carcinoma eventhough the size of sample is 
very small whereas AR is absent in 100% cases of Medullary and Papillary 
carcinoma. In Infiltrating Ductal Carcinoma and Mucinous carcinoma it is 
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seen in 60% of the cases. But these results are not statistically significant. 
(Table 18 & Chart 13) 
Table-18: Correlation of Histological Types and Expression of 
Androgen Receptor 
HISTOLOGICAL 
TYPES 
AR 
positive 
AR 
negative 
Total 
P 
value 
Apocrine 3(100%) - 3 
0.61 
 
IDC NOS 18(60%) 12(40%) 30 
Lobular 3(100%) - 3 
Medullary - 2(100%) 2 
Metaplastic 2(40%) 3(60%) 5 
Mucinous 3(60%) 2(40%) 5 
         Neuroendocrine 1(100%) - 1 
Papillary - 1(100%) 1 
Grand Total 30 20 50 
 
Left sided tumors show 11 cases positive with 57.8% positivity and right 
sided tumors show 19 cases positive with 61.2% of the cases. But this is not 
statistically associated. (Table 19 & Chart 14). 
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Chart-12: AR Expression with Age range 
 
Chart-13: AR Expression with Histological types 
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Table-19: Correlation of Side of the cancer with Expression of Andrgen 
Receptor 
Side of the cancer AR positive AR negative Total 
P value 
Left 11(57.8%) 8(42.2%) 19 
0.811964 
 
Right 19(61.2%) 12(38.8%) 31 
Grand Total 30 20 50 
 
Chart-14: AR with Side of the tumor. 
 
Smaller sized tumors show increased AR expression with T1 tumors 
showing 100% positivity and large sized tumors show decreased AR 
expression with T3 showing 36.3% positivity.(Table 20 & Chart 15) 
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Table-20: Correlation of Tumor size with Expression of Androgen 
Receptor 
SIZE OF TUMOR POSITIVE NEGATIVE TOTAL 
P 
value 
<2cm(T1) 2(100%) 0(0%) 2 
0.12 
 
2-5cm(T2) 24(64.8%) 13(35.2%) 37 
>5cm(T3) 4(36.3%) 7(63.7%) 11 
TOTAL 30 20 50 
 
Chart-15: AR with Size of the tumor. 
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Table-21: Correlation of grade of the tumor with Androgen Receptor. 
Grade AR positive AR negative Total P value 
I 6(60%) 4(40%) 10 
0.89 
II 6(60%) 4(40%) 10 
III 7(70%) 3(30%) 10 
Special types 11(55%) 9(45%) 20 
Total 30 20 50 
 
 Grade of the tumor is not significantly associated with Androgen 
Receptor expression in breast cancer with grade III showing 70%. (Table 21 
& Chart 16)  
Chart-16: AR Expression with grade of the tumor 
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Table-22: Correlation of Lymph node metastasis with Expression of 
Androgen receptor. 
LYMPH NODE 
STATUS 
AR 
positive 
AR 
negative 
Total 
P 
value 
NODE NEGATIVE 14(50%) 14(50%) 28 
0.1 NODE POSITIVE 16(72.7%) 6(27.3%) 22 
GRAND TOTAL 30 20 50 
 
Chart-17: AR Expression with Lymph node metastasis. 
 
 Androgen Receptor expression is seen more common in node positive 
tumors with 72.7% of AR positivity seen in node positive tumors.(Table 22, 
Chart 17)  
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Table-23: Correlation of Lymphovascular invasion with Expression of 
Androgen Receptor. 
Lymphovascular 
invasion 
AR positive AR negative Total 
P 
value 
Absent 17(53.1%) 15(46.9%) 32 
0.18 
 
Present 13(72.2%) 5(27.8%) 18 
Grand Total 30 20 50 
 
Tumors with Lymphovascular invasion show increased AR positivity with 
72.2% and it is not statistically significant. (Table 23 & Chart 18) 
Chart-18: Lymphovascular invasion with AR expression. 
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Table-24: Correlation of Lymphocytic infiltration with Expression of 
Androgen receptor. 
Lymphocytic 
infiltration 
AR positive AR negative Total 
P 
value 
Absent 18(60%) 10(40%) 28 
0.485 
 
Present 12(40%) 10(60%) 22 
Grand Total 30 20 50 
 
 AR expression is seen more commonly in tumors presenting with no 
Lymphocytic infiltration (60%) and it is not significantly associated. (Table 
24 & Chart 19) 
Chart-19: Lymphocytic infiltration with AR expression. 
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Table-25: Correlation of Tumor necrosis with Expression of Androgen 
receptors. 
Necrosis AR Positive AR Negative Total 
P value 
Absent 25(59.5%) 17(40.4%) 42 
0.874862 
 
Present 5(62.5%) 3(37.5%) 8 
Grand Total 30 20 50 
 
Tumors with necrosis show more AR positivity (62.5%) than tumors 
without necrosis (59.5%) though not statistically associated. (Table 25 & 
Chart 20) 
Chart-20: Necrosis with AR expression 
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Table-26: Correlation between Skin infiltration with Androgen 
Receptor 
Skin infiltration AR positive AR negative Total P value 
Absent 27(58.6%) 19(41.4%) 46 
0.5231 
 
Present 3(75%) 1(25%) 4 
Grand Total 30 20 50 
 
Presence of Skin infiltration by the tumor is not significantly associated 
with AR expression though it was found that 75% of tumors with Skin 
infiltration show AR positivity. (Table 26 & Chart 21)  
Chart-21: Skin infiltration with Androgen Receptor. 
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Table-27: Correlation between Estrogen and Androgen receptors 
ER expession AR Positive AR Negative Total 
P value 
ER-neg 10(41.7%) 14(58.3%) 24 
0.01101 
 
ER-pos 20(76.9%) 6(23.1%) 26 
Grand Total 30 20 50 
 
 ER positive tumors are more frequently associated with AR expression 
with 20 out of 26 tumors showing AR positivity constituting 76.9% and it 
was found that they are statistically significant with p value <0.05. (Table 
27 & Chart 22) 
Chart-22: Correlation of ER with AR expression. 
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Table-28: Correlation between Progesterone and Androgen receptors. 
PR expression Positive Negative Total P value 
PR-neg 11(42.3%) 15(57.7%) 26 
0.007862 
 
PR-pos 19(79.1%) 5(20.9%) 24 
Grand Total 30 20 50 
 
AR expression is significantly associated with Progesterone receptor 
expression showing 79.1% positivity in PR positive tumors. (Table 28 & 
Chart 23) 
Chart-23: Correlation of PR with AR expression. 
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Table-29: Correlation between Expression of HER2neu and Androgen 
receptor. 
HER2neu expression AR Positive AR Negative Total 
P value 
HER2-neg 21(56.7%) 16(43.3%) 37 
0.5886 
 
HER2-pos 9(69.3%) 4(30.7%) 13 
Grand Total 30 20 50 
 
AR positivity is seen more commonly in cases expressing HER2neu but 
56.7% of HER2neu negative tumors also express AR positivity but they are 
not statistically significant. (Table 29 & Chart 24) 
Chart-24: HER2neu expression with AR expression. 
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Table-30: Correlation between ER, PR and AR 
 
AR Positive AR Negative Total 
P value 
ER -,PR - 10(41.6%) 14(58.4%) 24 
0.028466 
 
ER+,PR- 1(50%) 1(50%) 2 
ER+,PR+ 19(79.1%) 5(20.9%) 24 
ER-,PR+ 0(0%) 0(0%) 0 
total 30 20 50 
 
The tumors which are positive for both ER and PR show maximum 
positivity for AR with 79.1% and it is statistically significant. (Table 30 & 
Chart 25) 
Chart-25: AR, PR expression with AR expression 
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Table-31: Correlation between Molecular classification and Androgen 
receptor 
 
Positive Negative Total 
P value 
Lumina A 16(76.1%) 5(23.9%) 21 
0.034 
 
Lumina B 4(80%) 1(20%) 5 
Basal like 5(31.25%) 11(68.75%) 16 
HER2neu 5(62.5%) 3(37.5%) 6 
Grand total 30 20 50 
 
Chart-26: Molecular classification with AR expression 
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 AR expression is significantly associated with Molecular classification 
showing increased expression in Lumina A and Lumina B subtypes. (Table 
31 & Chart 26) 
In this study the expression of AR found to be significantly 
associated with expression of ER, PR and Molecular classification. It is not 
significantly associated with other clinicopathological factors which can be 
attributed due to small sample size. 
 
 
  
 
 
 
 
 
 
 
 
 
DUCTAL CARCINOMA BREAST 
 
Figure 2: Grey white firm growth with irregular margins 
 
MUCINOUS CARCINOMA
 
Figure 3: Well circumscribed glistening gelatinous growth
  
PAPILLARY CARCINOMA 
 
Figure 4: Well circumscribed grey white growth with granular surface 
                                              
                                     APOCRINE CARCINOMA 
 
Figure 5: Well circumscribed grey white growth with cystic degeneration and 
hemorrhage
 MEDULLARY CARCINOMA 
 
Figure 6: Well circumscribed greywhite fleshy growth 
 
METAPLASTIC CARCINOMA 
 
Figure 7: well circumscribed grey white firm growth 
 
 
 
 
 LOBULAR CARCINOMA 
 
Figure 8: Well circumscribed Gray white 
 
NEUROENDOCRINE CARCINOMA 
 
Figure 9 :Well demarcated gray white tumor 
 
 
 INVASIVE DUCTAL CARCINOMA NOS - GRADE 1 
 
       
 
 
 
 
INVASIVE DUCTAL CARCINOMA NOS GRADE 2 
 
       
 
Figure 10: Invasive ductal carcinoma 
NOS tubule formations >75% tumor cells 
(40X) 
Figure 11: Malignant ductal epithelial cells 
with mild nuclear pleomorphism & low 
mitosis (400X) 
Figure 12: Sheets of malignant 
ductal epithelial  cells, 30% tubule 
formation (100X) 
Figure 13: Malignant ductal epithelial cells 
in sheets, 30% tubules and mild nuclear 
pleomorphism (400X) 
  INVASIVE DUCTAL CARCINOMA NOS GRADE 3 
 
       
 
 
 
 
MUCINOUS CARCINOMA  
 
       
 
  
Figure 14: Malignant ductal epithelial 
cells in sheets (100X) 
Figure 15: Malignant epithelial cell with 
marked pleomorphism and increased 
mitosis.(400x) 
Figure 16: Tumor nests floating in 
mucin (100X) 
Figure 17: Malignant ductal epithelial cells  
with mild nuclear pleomorphism and no 
mitosis (400X) 
 LOBULAR CARCINOMA 
 
               
 
 
 
 
MEDULLARY CARCINOMA 
 
 
              
 
 
 
 
  
 
 
 
 
Figure 18: Tumor cells arranged 
in lobular pattern with pagetoid 
spread around ductal 
elements(100X) 
Figure 19: Tumor cells arranged in 
singles in Indian file pattern (400X) 
Figure 20: nodular arrangement of 
tumor cells with lymphoplasmacytic 
infiltrate in periphery (100X) 
Figure 21: tumor cells in syncytial 
pattern with marked nuclear 
pleomorphism and prominent 
nucleoli  (400X) 
 PAPILLARY CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APOCRINE CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Tumor cells in papillary 
pattern (100X) 
Figure 23: Tumor cells in delicate papillary 
pattern (400X) 
Figure 24: Apocrine cells in papillary 
pattern (100X) 
Figure 25: Apocrine cells with abundant  
granular eosinophilic cytoplasm (400X) 
 METAPLASTIC CARCINOMA WITH SPINDLE 
DIFFERENTIATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROENDOCRINE CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 : Malignant epithelial cells with 
spindle cell differentiation (100x) 
Figure 27: Malignant spindle cells with 
multinucleated giant cell (400x) 
Figure 28: tumor cells in nests separated 
by  fibrovascular septa (100x) 
Figure 29: uniform oval shaped tumor 
cells with salt and pepper chromatin 
(400x) 
  
 
 
OTHER PROGNOSTIC FACTORS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30:Metastatic deposit in node 
(100X) 
Figure 31: Lymphovascular invasion 
(100x) 
Figure 33: Skin infiltration (100X) 
 
Figure 32 : Lymphocytic infiltration (100X) 
 ESTROGEN RECEPTOR EXPRESSION 
 
Figure 34: Invasive Ductal Carinoma NST. Positive nuclear staining (5+3) for ER 
 
PROGESTERONE RECEPTOR EXPRESSION 
 
Figure 35: Invasive Ductal Carcinoma NST. Positive nuclear staining (5+3) for PR 
 
 
 
 
 HER2neu EXPRESSION 
 
Figure 36: Invasive Ductal Carcinoma NST. Cytoplasmic positivity (3+) of 
HER2neu 
 
ANDROGEN RECEPTOR EXPRESSION 
 
Figure 37: Invasive Ductal Carcinoma NST. Positive nuclear staining (5+3) for 
Adrogen receptor. 
 
  
 
 
Figure 38: Lobular Carcinoma of Breast. Positive nuclear staining (5+3) for 
Androgen Receptor 
 
 
Figure 39: Apocrine Carcinoma of breast. Positive nuclear staining (5+2) for 
Androgen receptor. 
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DISCUSSION 
 Among the urban population breast carcinoma comprise the most 
common cause for cancer related mortality and it is the second most 
common cause in rural women. 
[131]
 It is a heterogeneous disease with 
varying clinical and pathological presentation.  
 Hence we can reduce the mortality of breast cancer by early detection, 
appropriate management and targeted therapies. Many theories underlie the 
pathogenesis of breast cancer and there are many prognostic factors. Apart 
from the prognostic markers like stage, grade, Lymph node status, ER, PR 
and HER2neu, many newer markers are under study. One such attempt was 
made to detect Expression of Androgen receptor.  
 In this present study, Immunohistochemistry was done in 50 cases and 
the expression was correlated with the clinicopathological factors. 
 Madras Medical College being a tertiary care center, among the 
surgical specimens received Breast tumors constitute 4.15% of all cases. 
Malignant breast tumors constitute 43.63% of all the breast specimens 
received. 
 The youngest age presented with breast cancer is 30 years and 
older age group reported to be 75 years with 52.5 as median age of 
presentation. This compared with study by Micello et al, 
[132]
 Carreno et al, 
[133]
 Hu et al, 
[134]
 Honma et al 
[135]
 showed that in Indian population there is 
 
 
70 
 
a shift in breast cancer presentation towards younger age group in the 
recent years. (Table 32) The highest incidence of breast cancer reported in 
41 to 50 year age group. This is in concurrence with the study done by 
Rajesh Singh Laishramet al. 
[136] 
Table-32: Comparison of Median age 
 Median age of presentation 
Micello et al.2010 
[132]
 58.7 
Carreno et al.2007 
[133]
 61 
Hu et al.2011 
[134]
 61 
Honma et al.2012 
[135]
 56 
Current study 52.5 
 
Among the histological types Invasive ductal carcinoma NOS type 
comprise the most common with 89.62%. This coincides with the study of  
Albrektsenet  al, 
[137] 
Shirley  SE  et  al 
[138]
 and  AM  Daudaet  al. 
[139]
  The 
incidence of invasive ductal carcinoma NOS type is higher in Indian 
population (89.62%) compared to that of western population accounting for 
the worse prognosis (Table 33) 
Majority of the breast cancers are seen in T2 category which is similar 
to the study by lakmini et al. But comparing with the study by Christine L 
[140]
 Carter et al the proportion of T2 in Indian population(70.28%)  is higher 
than in Western population(55.4%). (Table 34) 
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Table 33: Comparison of distribution of histological subtypes of breast 
cancers 
 
Histological subtypes 
AM 
Dauda et 
al 
[139]
 
Shirley 
SE et al 
[138]
 
Albrektsen  
et al 
[137]
 
Current 
study 
Invasive ductal 
carcinoma 
NOS 
 
78.8% 
 
69.3% 
 
81.4% 
89.62% 
Lobular carcinoma 6.7% 5.6% 6.3 % 1.42% 
Tubulolobular carcinoma - 0.5% - - 
Mixed carcinoma - - - - 
Mucinous carcinoma 2.4% 3.6% 2% 2.36% 
Micropapillary 
carcinoma 
- 0.5% - - 
Microinvasive 
carcinoma 
- 0.3% - - 
Papillary carcinoma 4.2% 3.5% - 0.47% 
Metaplastic carcinoma 2.4% 1.3 - 2.83% 
Tubular carcinoma - 0.8% 2% - 
Cribriform carcinoma - 0.1% - - 
Medullary carcinoma 3.6% 1% 1.1% 0.94% 
Apocrine carcinoma - - - 1.89% 
Adenoid cystic 
carcinoma 
- 0.1% - - 
Malignant phyllodes 1.8% - 0.4% - 
Neuroendocrine 
carcinoma 
- - - 0.47% 
Inflammatory carcinoma - 1.4% - - 
Other specific types - - 1.2% - 
Adenocarinomas 
unspecific 
 
- 
 
5.3% 
 
5.5% 
- 
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Table-34: Comparison of size of tumors (%) 
 
 
Size 
 
Christine L. 
Carter et al 
[140]
 
 
E  F S Al-Joudi 
et al 
[141]
 
 
Lakmini et 
al 
[142]
 
 
Current 
study 
T1 33.6 3.14 14.5 4.25% 
T2 55.4 19.37 74 70.28% 
T3 11 77.49 11.5 25.47% 
 
The Grade II tumors were more frequent than other grades of 
breast cancers. This observation is in concordance with the study carried 
out by Qiu Jet al 
[143] 
, Carey et al 
[144] 
and GG Van den Eynden et al 
[145]
 
(Table 35). 
Table 35: Comparison of grade of tumor (%) 
 
 
Grade 
 
Qiu J 
et al 
[143] 
 
Carey et 
al 
[144]
 
 
GG Van den 
Eynden et al 
[145] 
 
Current 
study 
Grade I 
 
33.3 25 32.63 20.00% 
Grade II 
 
       54 26 36.84 62.11% 
Grade III 12.7 49 30.53 17.89% 
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 60.85 % of the cases showed lymph node metastasis and 37.26% cases 
with 1-3 nodes positive. This results coincides with the study done by 
Jun   Qiu et al 
[143] 
and SE Shirley et al 
[138]
 who reported nodal metastasis 
in 60.32% and 75.7% of their cases. 
There were lymphocytic infiltration in 53.3%, skin infiltration in 
8.02% and necrosis in 32.5% of the cases, in concurrence to the 33% skin 
infiltration reported in the study conducted by Chanda Bewtra et al 
[146]
 and 
38.1% necrosis in the study conducted by Gloria Perio et al. 
[147] 
Table-36: Comparison of molecular classification
 
 Adedayo et al 
[148]
 Current study 
Lumina A 68.9 
41.50943 
Lumina B 10.2 
12.73585 
HER2neu positive 7.5 
14.15094 
Triple negative 13.4 
31.60377 
  
  Our study shows Maximum number of cases in Lumina A category 
constituting 41.5% of cases which is in concurrence with the study by 
Adedayo et al who shows maximum (68.9%) cases in Lumina A. (Table 36) 
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COMPARISON OF AR EXPRESSION WITH OTHER SUDIES 
 In this study AR was expressed in 60% of breast cancers which 
coincides with studies by Agoff et al 
[128]
, Park et al.
 [126]
 (Table 37) 
Table-37: Comparison of AR Expression 
 AR positivity % 
Park et al 
[126]
 58 
Yu et al 
[129]
 72 
Hu et al 
[134]
 79 
Peters et al 
[149]
 54 
Agoff et al 
[128]
 58 
Agrawal et al 
[117]
 43 
Current study 60 
 
The present study shows expression of AR more in the age group of 51-60 
years constituting 40% of all AR positive cases. But this is not statistically 
significant. This result coincides with study by park et al 
[126]
 which shows 
increased AR expression in age group over 35 years. 
 The current study shows increased expression of AR in Apocrine, 
Lobular and Neuroendocrine carcinoma and it is not statistically significant. 
But the study by Park et al 
[126]
 in which Loular carcinoma shows 83% 
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positivity and Leo A Neimeier et al 
[125]
  which shows AR positivity in 58.3% 
cases of Apocrine differentiation. (Table 38) 
Table-38: Comparison of AR Expression among Histological types 
 
AR positive % of respective category 
Park et al 
[126]
 Mishra e al 
[130]
 Current study 
IDC NOS 73.68 40.5 60 
Lobular 83.3 
37.5 
100 
Mucinous 41.7 60 
Medullary 25 0 
Tubular 100 - 
Papillary 81.8 0 
Metaplastic 
50 
40 
Apocrine 100 
Neuroendocrine 100 
 
 Park et al 
[126]
 shows that AR positivity in more in T1 stage (62.1%) and 
established a significant association. The present study also shows increased 
AR expression in T1 stage (100%) but it was not significantly associated. 
 70% of  grade III tumors are AR positive, 60% of grade II and 60% of 
grade I tumors are AR Positive but there is no significant association between 
them. Park et al 
[126]
 established a significant association between grade II 
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tumors and AR. Mishra et al 
[130]
 established a significant association between 
Lower grade tumors and AR.  
  In our study AR positivity is more common in Node positive cases 
constituting 72.72% cases and this result coincides with study by Park et al 
[126]
 who showed 69.2%. The study by Mishra et al 
[130]
 showed Maximum 
AR positivity in node negative tumors but none of the studies is statistically 
significant. 
 The current study shows that there is an inverse correlation between 
Lymphovascular invasion, Lymphocytic infiltration, Skin invasion, Presence 
of necrosis and Androgen receptor though it is not statistically significant. 
Correlation of AR with Hormonal Receptors. 
 In our study AR positivity is higher in cases which are ER positive 
constituting 76.9% of ER positive cases. This correlation is statistically 
significant. This result is in concordance with other studies. 
 76.9% cases of ER positive are AR positive and they are significantly 
associated. The comparison with other studies is given in table 39. 
 Yu et al 
[129]
 studied 564 cases and found 74.9% of  HER2neu negative 
tumors are AR positive. Similar study done by Park et al 
[126]
 with 413 cases 
shows 70.7% of HER2neu negative tumors are AR positive. Our study also 
shows similar results with 56.75% of HER2neu negative tumors with AR 
positivity though it was not statistically significant. A functional crosstalk 
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between AR and HER2neu signaling pathway has been shown in in vitro 
studies and gene expression profiling in ER negative tumors by Naderi et al 
[150]
 and Doane et al 
[113]
 
Table-39: Comparison of ER Expression with AR Expression 
 
ER positive % among 
AR positive tumors. 
PR positive % among 
AR positive tumors. 
Park et al 
[126]
 83.3 82.0 
Leo A Niemeier et 
al 
[125]
 
94.7 - 
A.K.Agrawal et al 
[117]
 43.7 60 
Yu et al 
[129]
 88.8 78.2 
Current study 76.9 79.16 
  
Table-40: Comparison of % of ER, PR positive tumors that are AR 
positive. 
 A.K.Agrawal et al 
[117]
 Agoff et al 
[128]
 Current study 
ER +,PR + 57 100 79.1 
ER +,PR - 34.4 67 50 
ER -,PR + 63.6 0 0 
ER -,PR - 60.3 50 4.16 
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The present study shows 79.1% of both ER and PR positive tumors are AR 
positive and this result is statistically significant. Similar results also obtained 
in studies by A.K.Agrawal et al 
[117]
 and Agoff et al. 
[128]
 (Table 40) 
Table-41: Comparison of AR expression in Molecular classification 
 Yu et al 
[129]
 
Leo A Niemeier 
et al 
[125]
 
Current study 
Lumina A 83.5 96 76.2 
Lumina B 75.6 86 80 
Triple negative 39 10 31.25 
HER2neu positive 55.8 63 62.5 
 
 80% of Luminal A tumors are AR positive and 76.2% of Luminal B 
tumors are AR positive and this study shows a significant association 
between them. (Table 41) 
 This study shows significant expression of Androgen receptor (60%)  in 
Primary breast cancer especially in ER and PR positive tumors. 
LIMITATIONS OF THE STUDY 
 
 The  cases  were  selected  on  the  basis  of  histopathological 
classification in the tertiary care Centre and not a population base 
study, which will not reflect the true prevalence of the general 
population 
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 HER2neu expression has an intermediate stain scoring of 2+ 
which requires FISH for grading it as negative or positive. 
 Gene expression profiling will give more accurate e x p r e s s i o n  
o f  A R  a n d  molecular subtypes than immunohistochemistry, but 
being expensive it cannot be applied to all patients. 
 Follow up details of the cases has not been available and Targeted 
therapies has not been done which helps to assess the prognostic and 
theranostic significance of Androgen receptor. 
.
  
 
SUMMARY 
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SUMMARY 
 This is the study conducted in Institute of Pathology, Madras Medical 
College, Chennai during the period between Jan 2013 to June 2015. It is a 
Prospective and retrospective study. Out of the 27576 specimens received 
during this period, 1515 cases were breast specimens. Of these 1145 were 
breast tumors constituting for 4.15% of all cases. 
 Non neoplastic cases were 370 and 484, 661 cases (including incisional 
and excisional biopsies) were benign and malignant breast tumors 
respectively, thus constituting 24.42% non-neoplastic cases, 31.95% benign 
cases and 43.63% malignant cases. 
 Of the total 364 Mastectomy specimens, detailed history regarding 
Patient’s age, sex, side of the breast involved, Grade, Lymph node 
involvement, Lymphocytic infiltration, Necrosis, Skin infiltration by tumor 
and Hormonal status like status of ER, PR, HER2neu were assessed for 212 
cases. For AR estimation 50 cases were randomly selected including 30 
Infiltrating Ductal carcinoma-NOS cases and 20 cases of special types like 
Mucinous, Medullary, Metaplastic, Apocrine, Papillary, Lobular and 
Neuroendocrine carcinoma. 
 Immunohistochemistic analysis of AR was done in these cases. Slides 
were evaluated and scoring was done by Alred scoring system and results 
were compared with other Histopathological parameters and Hormonal 
receptors like ER, PR and HER2neu status. 
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 Highest incidence of breast carcinoma occur in the age group of 41-50 years. 
 Infiltrating Ductal Carcinoma is the most common primary malignant 
neoplasm of breast constituting 89.6% of cases. 
 Most of the malignant tumors are Right sided. 
 70.3% of cancers are presented in the size range of 2-5cms. 
 Majority of the tumors are of Grade II accounting for 62.1% of all cases. 
 60.9% cases presented with Lymph node metastasis and majority of them 
with N1 stage. 
 Lymphovascular invasion was seen in 46.7% of cases and Lymphocytic 
infiltration seen in 53.3% cases.  
 Necrosis was present in 32.6% of cases 
 Skin infiltration was observed in 8% of cases 
 Estrogen receptor expression was observed in 51.42% cases and Progesteron 
receptor was observed in 46.7% cases. 
 26.89% of cases were positive for HER2neu. 
 As per Molecular classification, Lumina A constitute maximum number of 
cases with 41.5% and Lumina B constitute 12% cases. HER2neu alone 
positive in 14.15% case and Triple negative in 31.6% cases. 
 Androgen receptor expression was seen in 60% of cases. 
 More number of cases are AR positive in the age group of more than 60 years 
though it was not statistically significant 
 AR expression is seen in 100% cases of Apocrine carcinoma, Lobular 
carcinoma and Neuroendocrine carcinoma. Although this result was limited 
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by small sample size, many studies shows similar results. AR expression was 
minimal or absent in Medullary carcinoma, Metaplastic carcinoma and 
Papillary carcinoma. 
 Smaller size tumors show maximum positivity with 100% positivity observed 
in T1 cancers and this result is in concordance with many studies. 
 There is no association obtained between Grade and AR expression in this 
study though many studies show significant association with low grade 
tumors. 
 Many lymph node positive tumors are AR positive but not significantly 
associated. 
 Androgen receptor expression is more in cases with Lymphovascular 
invasion and cases without Lymphocytic infiltration. 
 Breast cancers with necrosis and skin involvement show increased AR 
expression. 
 ER positive tumors are significantly associated with AR expression than ER 
negative tumors. 41% of ER negative tumors also express AR. 
 AR expression is significantly more in PR positive tumors. 
 56% of HER2neu negative tumors are AR positive and 69.2% of HER2neu 
positive tumors are AR positive. 
 63.3% of total cases are Positve for all three markers-ER, PR, AR. And 41% 
of ER-/PR- tumors are AR positive. 
 AR expression is seen maximum in Luminal A and Luminal B subtypes of 
tumors. 
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 31.25% of Triple negative tumors(ER-/PR-/HER2neu-) are AR positive 
explaining the implication of AR related targeted therapy in these tumors. 
 In this present study AR is significantly associated with ER and PR positive 
tumors and Luminal A and Luminal B subtypes of Molecular classification. 
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CONCLUSION 
 In this study, the incidence of IDC-NOS type forms the highest among 
primary breast cancers. Luminal A subtype constitute majority of cases 
followed by Luminal B subtype. 
 AR is expressed in 60% of cases of Primary breast carcinoma. 
 The expression of AR is significantly associated with ER and PR 
expression and seen more in Luminal A and Luminal B subtype which have 
better prognosis and hence it could be an independent prognostic factor. 
 Even though the study was done only in a small number of cases AR is 
frequently expressed in Apocrine carcinoma, Lobular carcinoma and 
Neuroendocrine carcinoma. 
Although impact of AR in the outcome of breast cancer has not been 
established, its expression is tend to be seen in tumors of smaller size, Lymph 
node involvement. There is no association established between AR 
expression and grade. 
 AR is significantly expressed in some proportion of Triple negative 
breast cancer which implicate the use of Androgen related targeted therapy in 
these cases. 
In conclusion, AR is expressed in significant number of breast cancers 
and expression parallels ER and PR expression. It could be an independent 
prognostic marker and additional AR related targeted therapies can be done.  
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ANNEXURES 
  
 ANNEXURE – I 
PROFORMA 
 
 
 
 
Case number                 :                                         Name          : 
 HPE numbe                :                                         Age            :  
IP number                    :                                         Sex             :  
Clinical diagnosis          : 
Menstrual status               : 
 Risk factors if any           : 
Side of breast                : Right/Left 
 
 
Specimen                         : Simple Mastectomy / Modified radical mastectomy / Radical 
Mastectomy / Toilet mastectomy / Others 
 
 
 
GROSS 
 
 
Specimen size 
 
 
 
 
: 
 
 
Nipple areola and Skin 
 
 
Tumor size 
 
 
Appearance 
 
 
Resected margins 
 
: 
 
 
: 
 
 
: 
 
 
: Superior    : 
 
 
 
 
Tumor margin       : 
 
 
 
 
 
Inferior       : 
  
Medial      : 
 
 
Posterior   : 
 
Lateral       : 
 Associated findings                              : 
Total number of nodes dissected         : 
Largest node size                                 : 
 
 
 
 
 
MICROSCOPY 
 
 
Histological subtype                            : 
 
Histological score :                   Nuclear score: 
   
Mitotic score: 
 
Modified Scarf Bloom Richardson Grade:     I 
 
/ 
 
II 
 
/         III 
 
Skin                                                     :     Free / Involved 
 
 
Nipple & Areola                                   :    Free / Involved 
 
 
Margins :         Superior      : Free / Involved                        Inferior : Free / Involved  
                       Medial       : Free / Involved                          Lateral  : Free / Involved  
                      Posterior      : Free / Involved 
Lymphatic invasion                             : Present / Absent 
Vascular invasion                                : Present / Absent 
Lymphocytic infiltration                          : P resent / Absent 
Necrosis                                               : P resent / Absent 
Associated breast lesions                     : 
Total number of nodes dissected         : 
Number of nodes involved                  :
 ANNEXURE II 
WHO HISTOLOGICAL CLASSIFICATION OF EPITHELIAL BREAST 
TUMORS 
INVASIVE BREAST CANCERS                                            NON INVASIVE BREAST CANCERS 
Invasive ductal carcinoma not otherwise specified           Ductal carcinoma in situ 
Mixed type carcinoma                                                        Lobular carcinoma in situ 
Pleomorphic carcinoma                                                     Atypical papilloma 
Carcinoma with osteoclastic type of giant cells                 BENIGN EPITHELIAL TUMORS 
Carcinoma with choriocarcinomatous features                  Tubular adenoma 
Carcinoma with melanotic features                                     Lactating adenoma 
Invasive lobular carcinoma                                                 Apocrine adenoma 
Tubular carcinoma                                                              Pleomorphic adenoma 
Invasive cribriform carcinoma                                            Ductal adenoma 
Medullary carcinoma                                                          Papilloma 
Mucinous carcinoma                                                           FIBROEPITHELIAL TUMORS 
Cystadenocarcinoma                                                           Fibroadenoma 
Signet ring carcinoma                                                         Phyllodes tumor 
Neuroendocrine tumors                                                          Benign 
Solid neuroendocrine carcinoma                                            Borderline 
Atypical carcinoid tumor                                                       Malignant 
Small cell/oat cell carcinoma                                   Periductal stromal sarcoma 
Large cell neuroendocrine carcinoma                     Mammaryhamartoma
Invasive papillary carcinoma 
Invasive micropapillary carcinoma 
Metaplastic carcinoma 
Apocrine carcinoma 
Pure epithelial metaplastic carcinoma 
 
INTRADUCTAL PROLIFERATIVE 
LESIONS 
Atypical ductal hyperplasia 
Flat epithelial atypia 
Usual epithelial hyperplasia
Squamous cell carcinoma                                       METASTATIC TUMORS 
Adenocarcinoma with spindle cell metaplasia 
Adenosquamous carcinoma 
Mucoepidermoid carcinoma 
Mixed epithelial/mesenchymal metaplastic carcinoma 
Lipid rich carcinoma 
Secretory carcinoma 
Oncocytic carcinoma 
Adenoid cystic carcinoma 
Acinic cell carcinoma 
Glycogen rich carcinoma 
Sebaceous carcinoma 
Inflammatory carcinoma 
Intraductal papillary carcinoma 
Intracystic papillary carcinoma 
Microinvasive carcinoma
 ANNEXURE III 
 
 
NOTTINGHAM MODIFICATION OF SCARF BLOOM 
RICHARDSON GRADING SYSTEM 
 
 
TUBULE FORMATION                                                   SCORE 
 
Tubule formation in >75% of the tumor                                  1 
 
Tubule formation in 10 to 75% of the tumor                           2 
 
Tubule formation in <10 % of the tumor                                 3 
 
 
 
NUCLEAR PLEOMORPHISM                                        SCORE 
 
Minimal variation in size and shape of nuclei                        1 
 
Moderate variation in size and shape of nuclei                      2 
 
Marked variation in size and shape of the nuclei                   3 
 
 
 
MITOTIC RATE                                                               SCORE 
 
<10 Mitosis per 10 high power field                                      1 
 
10 to 20 mitosis per 10 high power field                                2 
 
>20 mitosis per 10 high power field                                       3 
 
 
 
GRADE                                                                              SCORE 
 
Grade 1:                                                                               3, 4, 5 
 
Grade 2:                                                                               6, 7 
 
Grade 3:                                                                               8, 9
  
 
ANNEXURE IV 
 
 
 
IMMUNOHISTOCHEMISTRY PROCEDURE 
 
 
1. 4μ thick sections were cut from formalin fixed paraffin embedded tissue samples 
and transferred to gelatin-chrome alum coated slides. 
2.        The slides were incubated at 58ºC for overnight. 
3.        The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4.        The sections were dehydrated with absolute alcohol for 5 minutes x 2 changes. 
5.        The sections were washed in tap water for 10 minutes. 
6.        The slides were then immersed in distilled water for 5 minutes. 
7. Heat induced antigen retrieval was done with microwave oven in  appropriate 
temperature with appropriate buffer for 20 to 25 minutes. 
8.        The slides were then cooled to room temperature and washed in running tap water 
for 5 minutes. 
9.        The slides were then rinsed in distilled water for 5 minutes. 
10.      Wash with appropriate wash buffer (phosphate buffer) for 5 minutes x 2 changes. 
11.      Apply peroxidase block over the sections for 10 minutes. 
12.      Wash the slides in phosphate buffer for 5 minutes x 2 changes. 
13.      Cover the sections with power block for 15 minutes. 
14. The sections were drained (without washing) and appropriate primary antibody 
was applied over the sections and incubated for 45 minutes. 
15.      The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
16.      The slides were covered with Super Enhancer for 30 minutes. 
17.      The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
18.      The slides were covered with SS Label for 30 minutes. 
19.      Wash in phosphate buffer for 5 minutes x 2 changes. 
20.      DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1ml of 
DAB buffer. 
21.      DAB substrate solution was applied on the sections for 8 minutes. 
22.      Wash with phosphate buffer solution for 5 minutes x 2 changes. 
23.      The slides are washed well in running tap water for 5 minutes. 
24.      The sections were counterstained with Hematoxylin stain for 2 seconds (1 dip). 
25.      The slides are washed in running tap water for 3 minutes. 
26.      The slides are air dried, cleared with xylene and mounted with DPX.
  
 
 
 
ANNEXURE V 
 
 
 
QUICK SCORE SYSTEM- ER, PR and AR 
Score for Proportion Score for Intensity 
0 = no staining 
1 = <1 percent nuclei staining 
2 = 1-10 percent nuclei staining 
3 = 11-33 percent nuclei staining 
4 = 34-66 percent nuclei staining 
5 = 67-100 percent nuclei staining 
0 = no staining 
1 = weak staining 
2 = moderate staining 
3 = strong staining 
 
 
The scores are added together to obtain a total score that can range from 0 to 8. 
Tumors scoring 2 or less are negative and have a negligible chance of response. 
 
 
STAINING PATTERN AND HER2 NEU SCORING 
 
STAINING PATTERN SCORE HER 2/neu 
ASSESSMENT 
No  staining  or  membrane  staining 
 
observed in <10% of tumor cells 
0 Negative 
A faint/barely perceptible membrane 
 
staining  observed  in  >10%  of  the tumor 
cells 
1+ Negative 
A   weak   to   moderate   complete 
 
membrane    staining    observed    in 
 
>10% of the tumor cells. 
2+ Positive 
A    strong    complete    membrane 
 
staining  observed  in  >30%  of  the tumor 
cells. 
3+ Positive 
 ANNEXURE-VI 
 
TNM Classification of carcinomas of the breast: 
T   - Primary Tumor  
TX  - Primary tumor cannot be assessed 
TO  - No evidence of primary tumor 
TIS  - Carcinoma in situ 
TIS (DCIS) - Ductal carcinoma in situ 
TIS (LCIS) - Lobular carcinoma in situ 
TIS (Paget) - Paget disease of the nipple with no tumor 
Note : Paget disease associated with a tumor is classified according to the size of the tumor 
 
T1 - Tumor 2 cm or less in greatest dimension 
TMIC - Micro invasion 0.1 cm or less in greatest dimension 
T1a - more than 0.1 cm but not more than 0.5cm in greatest dimension 
T1b - more than 0.5 cm but not more than 1 cm in greatest dimension. 
T1c - more than 1 cm but not more than 2 cm in greatest dimension 
T2 - Tumour more than 2 cm but not more than 5 cm in greatest  
  dimension. 
T3 - Tumour more than 5 cm in greatest dimension 
T4 - Tumour of any size with direct extension to chest wall or skin only 
as described in T4a to T4d. 
Note : Chest wall includes ribs, intercostals muscles, and seratus anterior muscle but not pectoral 
muscle. 
 
T4a - Extension to chest wall 
T4b - Oedema (including peau’d orange) ulceration of the skin of the  
  breast (or) satellite skin nodules confined to the same breast. 
T4c - Both 4a and 4b, above 
T4d - Inflammatory Carcinoma. 
 
Notes : Microinvasion is the extension of cancer cells beyond the basement membrane into the 
adjacent tissues with no focus more than 0.1 cm in greatest dimension. When there are multiple 
foci of microvasion, the size of only the largest focus is used to classify the microinvasion. 
     
 Inflammatory carcinoma of the breast is characterized by diffuse brawny induration of 
the skin with an erysipeloid edge, usually with no underlying mass. If the skin biopsy is negative 
 and there is no localized measurable primary cancer, the T category is PTX when pathologically 
staging a clinical inflammatory carcinoma (T4d). Dimpling of the skin, nipple retraction, or other 
skin changes, except those in T4p and T4d may occur in T1, T2, or T3 without affecting the 
classification. 
N - Regional Lymph Nodes 
Nx - Regional lymph nodes cannot be assessed previously removed 
N0 - No regional lumph node metastasis. 
N1 - Metastasis in movable ipsilateral axillary lymph node (s) 
N2 - Metastasis in fixed ipsilateral axillary lymph node (8) or in  
  Clinically apparent ipsilateral internal mammary lymph node(s) in  
  the absence of clinically evident axillary lymph node metastasis. 
N2a - Metastasis in axillary lymph node(s) fixed to one another or to other 
  structures. 
N2b - Metastasis only in clinically apparent internal mammary lymph  
  node (s) and in the absence of clinically evident axillary lymph node  
  metastasis. 
N3 - Metastasis in ipsilateral infraclavicular lymph node (s) with or  
  without axillary lymph node involvement, or in clinically apparent  
  ipsilateral internal mammary lymph node (s) in the presence of  
  clinically evident axillary lymph node metastasis or metastasis in  
  ipsilateral supraclavicular lymph node (s) with or without axillary or  
  internal mammary lymph node involvement. 
N3a - Metastasis in intraclavicular lymphnode(s) 
N3b - Metastasis in supraclavicular lymph nodes 
M - Distant metastasis 
Mx - Distant metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis 
 
                                               
 
  
 
 
 
MASTER CHART 
S.NO HPE NO Age Side TL SIZE HT G LVI LYI N SK LN AL ER PR H2N AR 
1 24/14 50 R CQ 6X4X3 IDC NOS III P P A A 16/17 ADH POS POS NEG   
2 328/14 63 R UOQ 4X3X3 IDC NOS II P A A A   3/5  FCD POS POS NEG   
3 366/14 55 L UIQ 2X2X2 IDC NOS II A A A A   3/8  FCD POS POS NEG   
4 407/14 43 R UIQ 4X3X2 IDC NOS I A P A A   4/5  FCD POS POS POS   
5 410/14 70 R CQ 5X2X1 IDC NOS II A A P A 0/9 FA NEG NEG NEG   
0 706/14 57 L LOQ 6X4X2 IDC NOS I A P A A 0/5   NEG POS POS   
7 724/14 37 L CQ 1X1X1 IDC NOS III P A P A   1/4    POS POS NEG   
8 1034/14 53 R LOQ 4X2X2 IDC NOS II P A P P   2/5  ADH NEG NEG NEG   
9 1082/14 52 R CQ 9X5X1 IDC NOS II P P A A   2/7  FCD POS POS POS   
10 1126/14 44 R CQ 4X2X2 IDC NOS I A A P A   3/5  FCD POS NEG NEG   
11 1151/14 45 L UOQ 6x6x3 IDC NOS II p p p P   1/9  DCIS POS POS NEG   
12 1692/14 45 L UOQ 6X5X2 IDC NOS I A P A A 0/7   POS POS NEG 0+0 
13 1793/14 75 L CQ 5X5X3 IDC NOS II P P P A   1/2  FCD NEG NEG NEG   
14 1964/14 40 R UOQ 3X2X1 IDC NOS II A A A A 0/3   NEG NEG NEG   
15 2003/14 53 L CQ 2X1X1 IDC NOS II A P P A 0/3   NEG NEG POS   
16 2177/14 55 R UOQ 7X5X3 IDC NOS II A A A A   2/5  FCD POS POS NEG   
17 2237/14 49 R CQ 9X5X4 IDC NOS II A P A P 0/14 FCD POS NEG NEG   
18 2355/14 37 L UOQ 4X4X3 IDC NOS II A P A A 19/20   NEG NEG POS 0+0 
19 2506/14 35 L LIQ 6X5X4 METAPLASTIC   A P P A 0/9   NEG NEG NEG 1+4 
20 2758/14 45 L CQ 10X9X8 IDC NOS II A P A P   3/4    NEG POS NEG   
21 2751/14 45 L CQ 5X1X1 IDC NOS I A P A A   2/3  FCD NEG NEG NEG   
22 2899/14 45 R LIQ 2X2X1 IDC NOS I P A A A 0       FCD POS POS NEG   
23 3044/14 35 L UOQ 4X3X2 IDC NOS II P A P A   6/13   POS POS NEG   
24 3072/14 33 L CQ 4X3X2 IDC NOS I P A A A 0/8 FCD POS POS NEG 1+4 
25 3188/14 45 R CQ 6X5X4 IDC NOS I A A A A   2/7    NEG NEG NEG   
26 3251/14 47 R UOQ 3X2X2 IDC NOS II A A A A 0/2   POS NEG NEG   
27 3261/14 44 R UIQ 5X2X2 IDC NOS I A A A A 0       FCD POS POS NEG   
28 3309/14 55 L UIQ 4X2X1 IDC NOS II P P A A   1/2  FCD NEG NEG NEG   
29 3340/14 45 R CQ 5X4X4 IDC NOS II P P A A   3/4  DCIS NEG POS NEG   
30 3349/14 49 L LOQ 3X3X2 IDC NOS I P P P A   3/13 FA NEG NEG NEG   
31 3462/14 45 R CQ 5X4X4 IDC NOS I P P P A 10/13   NEG NEG NEG   
32 3509/14 50 L LOQ 3X3X3 IDC NOS I A A A A   1/5    POS NEG POS   
33 3536/14 58 R UIQ 2X2X1 LOBULAR   A A A A 0/5   POS POS NEG 2+5 
34 3648/14 47 L UOQ 3X3X2 IDC NOS II P A A A   1/8  FCD POS NEG NEG   
35 3686/14 40 L UOQ 4X3X3 IDC NOS II A A A A   1/10   NEG NEG NEG   
36 4029/14 50 R UIQ 3X3X2 IDC NOS II A P A A 14/23 FCD NEG NEG NEG   
37 4108/14 63 R UOQ 2X2X1 IDC NOS I A P A A   1/8  FA NEG NEG NEG   
38 4240/14 50 L CQ 1X1X1 IDC NOS I P A A A 0/3 UDH POS POS NEG   
39 4290/14 48 L UIQ 7X2X3 IDC NOS II P A A P   7/9  FCD NEG NEG NEG   
40 4589/14 49 R UOQ 2X1X1 IDC NOS III P P P A   3/4  SA POS POS POS 0+0 
41 4590/14 37 L UIQ 5X3X2 IDC NOS I A A A A   9/10 DCIS NEG POS NEG   
42 4603/14 42 R UIQ 1X1X1 IDC NOS II P P P A 11/12 DCIS POS POS NEG   
43 4757/14 52 R UOQ 4X3X2 IDC NOS II P P A A   4/7  FCD POS POS NEG   
44 4812/14 63 L CQ 6X5X3 IDC NOS II P P A A 0/1 FCD POS POS NEG   
45 4814/14 46 L CQ 5X4X2 IDC NOS II A A A P 11/17 FCD NEG NEG NEG   
46 4818/14 60 R CQ 3X2X2 MUCINOUS   A A A A 0         POS NEG NEG 0+0 
47 5009/14 65 R LOQ 5X4X2 NEUROENDOCRINE   P P A A   1/2    POS NEG NEG 1+5 
48 4890/14 50 L CQ 5X2X2 PAPILLARY   A A A A 0         POS POS NEG 0+0 
49 5102/14 52 L UIQ 9X6X4 IDC NOS II P A A A   1/5    POS NEG POS   
50 5206/14 51 L CQ 8X2X2 IDC NOS II A A A P   4/5  FCD NEG NEG NEG   
51 5277/14 45 R CQ 4X3X2 IDC NOS II A A A A 0/14 FCD POS NEG NEG   
52 5306/14 60 R CQ 1X1X1 IDC NOS II P P A A   6/7  FCD NEG NEG NEG   
53 5332/14 56 R CQ 3X3X1 MUCINOUS   A A A A 0/7 FCD POS POS NEG 1+2 
54 5353/14 50 L CQ 3X3X1 MEDULLARY   A P A A   1/5  FCD NEG NEG NEG 0+0 
55 5427/14 45 R CQ 4X2X2 IDC NOS II A A A A   1/5  FCD POS POS NEG   
56 5429/14 49 R CQ 4X3X2 IDC NOS II A A A A   4/9  FCD POS POS NEG   
57 5819/14 54 R CQ 8X6X3 METAPLASTIC   A P A A 0/10   NEG NEG NEG 0+0 
58 6189/14 65 R UOQ 6X4X3 MUCINOUS   P A A A   1/9    POS POS NEG 1+5 
59 6194/14 45 L CQ 9X5X1 IDC NOS II P P A P   1/8  FCD POS POS NEG   
60 6219/14 65 L CQ 4X3X3 IDC NOS III P A P A 0/7 FCD NEG NEG NEG   
61 6266/14 70 L CQ 6X4X2 IDC NOS II A A A P 0/4 FCD POS POS NEG 0+0 
62 6309/14 60 R CQ 4X3X2 IDC NOS I A P A A 14/19 UDH POS POS NEG 1+2 
63 6376/14 37 L LOQ 4X3X1 IDC NOS II A A P A   4/9  FA NEG NEG NEG   
64 6655/14 50 L CQ 3X3X1 IDC NOS III P A A A   2/3  FCD POS POS POS 0+0 
65 7004/14 35 R CQ 4X3X2 IDC NOS II P P P A 0/7 DCIS NEG POS POS   
66 7125/14 67 R UOQ 2X1X1 IDC NOS II A P P A 0/6 FCD POS POS NEG   
67 7209/14 55 L LOQ 1X1X1 IDC NOS II P P A A 0/7 FCD POS POS NEG   
68 7302/14 48 L UOQ 3X2X1 IDC NOS II P A A A 0/3   NEG NEG NEG   
69 7321/14 52 R CQ 5X3X3 APOCRINE   A P A A   1/4    NEG NEG NEG 2+5 
70 7332/14 47 R UOQ 3X3X2 IDC NOS II A A A A 0       FCD NEG NEG POS 0+0 
71 7435/14 46 R UIQ 5X4X2 IDC NOS II A A P A   5/8  FCD NEG NEG NEG   
72 7516/14 55 R CQ 3X2X2 IDC NOS II A A A A   1/11   POS POS POS   
73 7559/14 63 R UOQ 1X1X1 APOCRINE   A P A A   4/19   NEG NEG NEG 1+2 
74 7721/14 33 R UIQ 4X4X3 IDC NOS II A P P A   9/10 FA POS POS NEG   
75 7733/14 52 R CQ 3X2X2 IDC NOS II P P A A   3/8  SA POS POS NEG 0+0 
76 7755/14 46 R UOQ 3X3X3 MEDULLARY   A P A A 0         NEG NEG NEG 0+0 
77 7839/14 57 L CQ 3X2X1 IDC NOS II A P P A   4/5    NEG NEG NEG   
78 8076/14 56 R UOQ 1X1X1 IDC NOS II P A P P   9/10 DCIS POS NEG POS   
79 8280/14 60 R CQ 2X2X2 IDC NOS II A P A A 0/5 FCD NEG NEG NEG   
80 8287/14 55 R CQ 3X2X2 IDC NOS II P A A A   1/4    POS NEG NEG   
81 8327/14 55 L UOQ 3X2X2 IDC NOS III P P P A   2/5  FCD NEG NEG NEG   
82 8383/14 53 L UOQ 6X4X4 IDC NOS II P P P A   2/7    NEG NEG NEG   
83 8459/14 46 L UOQ 9X8X4 IDC NOS II P P P P   2/9  FCD POS POS NEG   
84 8503/14 60 R CQ 5X5X4 IDC NOS III P P A A 0       DCIS NEG NEG NEG 0+0 
85 8572/14 40 L UIQ 1X1X1 APOCRINE   A A A P 0/17 DCIS NEG NEG NEG 2+5 
86 8589/14 37 R LIQ 4X2X1 IDC NOS III P P A A 0/4   POS POS NEG   
87 8672/14 50 R CQ 3X2X2 IDC NOS I P P A A   1/11 FA NEG NEG POS   
88 8932/14 40 L CQ 2X2X1 IDC NOS I P P A A   1/6  FA POS POS NEG   
89 9065/14 30 L UOQ 4X3X3 IDC NOS III A A A P   1/2  FCD POS POS POS 2+4 
90 9083/14 45 L UOQ 2X1X1 IDC NOS II P P P A 0/4   POS POS NEG   
91 9229/14 57 L LOQ 2X2X1 IDC NOS II P A A A   5/6  FCD NEG NEG POS   
92 9247/14 65 L UOQ 4X2X1 IDC NOS I A P A A   2/3  DCIS POS POS NEG 2+5 
93 9275/14 60 L CQ 8X5X4 IDC NOS III P A P P 0       FCD POS POS NEG   
94 9437/14 46 L UIQ 3X2X2 IDC NOS III A A P A 0/4   NEG NEG NEG   
95 9438/14 56 R CQ 2X2X1 IDC NOS II A A A A   4/5    POS POS NEG   
96 9444/14 30 R CQ 3X2X2 METAPLASTIC   A A A A 0/5   NEG NEG NEG 0+0 
97 9667/14 40 L CQ 5X4X2 IDC NOS II A P P A   1/3  FCD POS POS NEG   
98 9762/14 44 R LOQ 4X3X2 IDC NOS II P P P A 0/2 FA POS POS POS   
99 9956/14 40 L UIQ 6X4X4 IDC NOS I A P A A 0/5 FA POS POS NEG   
100 10005/14 52 L CQ 3X2X2 IDC NOS II A P A A   1/12 FCD NEG NEG POS   
101 10119/14 31 R UOQ 6X4X4 IDC NOS II A A A A 0/16 FCD POS POS NEG   
102 10371/14 40 R CQ 3X2X1 IDC NOS II P P A A   7/11 ADH POS POS NEG   
103 10407/14 43 R CQ 4X3X3 IDC NOS I P A A A   2/19 FCD NEG NEG POS 1+3 
104 10449/14 45 L CQ 6X4X4 IDC NOS III A A A A   1/13 FCD NEG NEG NEG 0+0 
105 10469/14 45 R CQ 2X1X1 IDC NOS II P A P A   3/5  FA POS POS NEG   
106 10540/14 53 L UOQ 2X2X1 IDC NOS II P A P A   4/5  FCD POS POS POS 3+5 
107 10598/14 67 L CQ 3X3X2 IDC NOS II P A A A 0/7 FCD POS NEG POS   
108 10850/14 55 R CQ 7X6X2 IDC NOS II P A A A   1/4  FA NEG NEG POS   
109 10939/14 50 R CQ 6X4X3 IDC NOS III P P A A 16/17 ADH POS POS NEG 0+0 
110 11008/14 63 R UOQ 4X3X3 IDC NOS II P A A A   3/5  FCD POS POS NEG 1+2 
111 11141/14 50 R UOQ 7X6X6 IDC NOS II A P P P 0/8 FCD POS POS POS   
112 11184/14 67 L CQ 4X3X3 IDC NOS III A P A A 0/8 FCD NEG NEG NEG   
113 11314/14 45 L CQ 2X2X2 IDC NOS II A A P A 0/8 FCD NEG POS POS   
114 11413/14 50 R CQ 3X3X2 IDC NOS II A P P A 0         NEG NEG POS   
115 11474/14 50 L UOQ 3X2X2 IDC NOS II P P P A 0/12 FCD NEG NEG NEG   
116 11537/14 65 L UOQ 3X3X3 IDC NOS III A A A A 0/12 FCD POS POS NEG 2+5 
117 11719/14 42 L UOQ 3X2X2 IDC NOS I P P P A   1/10 FCD NEG NEG POS   
118 11889/14 37 R UOQ 3X2X1 IDC NOS II A A A A   2/5  FCD POS NEG NEG   
119 11928/14 60 R CQ 6X2X2 IDC NOS II P P P A 0/2   NEG NEG POS   
120 11994/14 42 R CQ 6X3X3 IDC NOS II A P A A   3/7    NEG NEG POS   
121 46/15 57 L CQ 5X4X4 IDC NOS I A A A A 0/7 FCD NEG NEG POS 0+0 
122 122/15 45 L CQ 6X4X4 IDC NOS II A A P A 0/6 FCD NEG NEG POS   
123 339/15 40 R LOQ 3X2X2 IDC NOS II A A A A 0/5 FCD NEG NEG NEG 0+0 
124 352/15 46 R CQ 3X2X2 IDC NOS II P A A A 0/4 FCD NEG NEG POS   
125 412/15 55 L LIQ 3X3X2 IDC NOS III P P A A   1/10 FCD NEG NEG POS   
126 617/15 45 R CQ 6X3X3 IDC NOS I A P P A   6/7    NEG NEG POS   
127 703/15 55 L CQ 2X2X1 IDC NOS II P A P A 0         POS POS NEG 3+5 
128 1097/15 40 R CQ 8X8X6 IDC NOS III P A A P 0/12 ADH NEG NEG POS 2+4 
129 1157/15 50 R LIQ 6X5X4 IDC NOS II A A A A 0/11 FCD NEG NEG NEG   
130 1240/15 55 R UIQ 2X2X2 IDC NOS I A P A A 0/10   NEG NEG NEG 0+0 
131 1198/15 30 L LOQ 4X3X2 IDC NOS I A P A A   5/8  FCD POS POS NEG   
132 1334/15 37 R CQ 3X3X2 IDC NOS II A A A A 0/6 FCD POS POS NEG   
133 1424/15 50 R UOQ 5X3X1 IDC NOS I A A A A   4/9  DCIS POS POS POS 3+5 
134 1586/15 60 L UOQ 12X9X8 METAPLASTIC   A A P A 0/22 FCD NEG NEG NEG   
135 1590/15 60 R CQ 5X3X2 IDC NOS II A P A A 0/7 FCD NEG NEG POS 1+4 
136 1600/15 35 L UIQ 8X4X3 IDC NOS II P P P P 13/16 FCD POS POS POS   
137 1689/15 50 L UOQ 5X4X3 IDC NOS II P A A A 0/3 FCD POS NEG NEG   
138 1968/15 55 R CQ 6X4X2 IDC NOS III A P P A 0/3 DCIS NEG NEG NEG 0+0 
139 2044/15 45 R LOQ 2X2X2 IDC NOS II A P P A   4/7  FCD NEG NEG POS 1+4 
140 2327/15 33 R LOQ 3X2X1 IDC NOS I P P A A 0       DCIS POS POS POS   
141 2741/15 48 R CQ 5X4X2 IDC NOS I A A P A 0/16 FCD NEG NEG POS 1+4 
142 2840/15 43 L CQ 4X3X3 IDC NOS II P A P A   1/2  DCIS POS POS NEG   
143 2849/15 46 R LOQ 3X2X2 IDC NOS I A A P A 0/3 FCD POS POS NEG   
144 2858/15 55 L LIQ 3X2X2 IDC NOS II A P A A   3/10 DCIS NEG NEG NEG   
145 2863/15 50 L UOQ 2X2X1 IDC NOS III P P P A   1/4  FCD NEG NEG NEG 0+0 
146 2995/15 40 L UIQ 5X3X2 IDC NOS II A P P A 0/6   NEG NEG POS   
147 3115/15 54 R UOQ 2X2X1 IDC NOS II A P P A 0/10 FCD NEG NEG NEG   
148 152/13 43 L UIQ 5X4X2 IDC NOS III P P A A   5/11 SA NEG NEG NEG   
149 158/13 37 L UIQ 6X2X1 IDC NOS III P P A A   6/7    POS POS NEG   
150 270/13 48 L UIQ 2X2X1 IDC NOS III P P P A   6/7  FA NEG NEG POS   
151 336/13 65 R UOQ 3X2X2 IDC NOS II A A A A   3/10   NEG NEG NEG   
152 575/13 55 R CQ 4X3X3 IDC NOS II A A A A 0/9 FCD NEG NEG NEG   
153 1012/13 52 L LOQ 18X16X9 IDC NOS II P P A A   1/10 FCD NEG NEG NEG   
154 1069/13 62 R UOQ 4X4X3 IDC NOS I P P A A 11/13   POS NEG NEG   
155 1081/13 43 R CQ 4X2X2 IDC NOS II P P A A   1/4  FCD POS POS NEG   
156 1434/13 54 R UOQ 3X2X2 IDC NOS III P P A A   1/11 SA POS POS NEG   
157 1472/13 43 L CQ 5X4X3 IDC NOS II P P P A   2/3  DCIS NEG NEG NEG   
158 1721/13 38 L UOQ 5X3X3 IDC NOS III A P A A   1/8  FA NEG NEG NEG   
159 1873/13 60 L LIQ 6X5X4 IDC NOS III A P A A 0/11 DCIS NEG NEG NEG   
160 1899/13 50 L CQ 3X2X2 IDC NOS III A A A A   4/7  FCD NEG NEG NEG   
161 2351/13 35 L UOQ 4X3X3 IDC NOS III P P P A   4/9  SA NEG NEG NEG   
162 2775/13 45 R CQ 5X5X1 IDC NOS II P A P A 0/13   NEG NEG POS   
163 2959/13 65 L CQ 5X3X1 IDC NOS II A A A A   1/4  FCD POS POS NEG   
164 2984/13 46 L UOQ 3X3X3 IDC NOS II A P A A   1/10 FCD NEG NEG NEG   
165 3074/13 31 R LIQ 3X2X1 IDC NOS II A A P A   1/2    POS POS POS   
166 3176/13 55 R UIQ 5X3X3 IDC NOS II P P P A   3/5    POS POS NEG   
167 3240/13 46 L LOQ 4X4X4 IDC NOS II P A A A 0/8   NEG NEG NEG   
168 3249/13 60 L CQ 7X6X2 IDC NOS II A P P A   3/7  FCD NEG NEG POS   
169 3379/13 37 R UOQ 2X2X2 IDC NOS II P P P A 0/6 FCD POS POS NEG   
170 3428/13 43 R UOQ 4X3X3 IDC NOS I A P A A   4/5  FCD POS POS NEG   
171 3446/13 55 R CQ 3X3X2 IDC NOS III P P A A   1/10 SA POS POS POS   
172 3496/13 55 L UIQ 8X8X6 IDC NOS II A A A A 0/12   NEG NEG POS   
173 3501/13 54 R UOQ 4X4X3 IDC NOS II P P A A 0/3   NEG NEG NEG   
174 3928/13 43 R CQ 3X2X2 IDC NOS II P P A A   2/5  FA NEG NEG POS   
175 4161/13 48 L LOQ 4X3X3 IDC NOS I A P A A   7/8  FA POS POS NEG   
176 4478/13 33 L UOQ 7X6X5 IDC NOS III P A A A   1/4  FCD POS POS NEG   
177 4753/13 60 L UIQ 6X4X2 IDC NOS III A A P A 0/6   POS POS POS   
178 4918/13 35 R CQ 8X4X3 IDC NOS II P P A A 0/3 DCIS NEG NEG POS   
179 5429/13 62 L UIQ 3X3X2 IDC NOS II A P A A   6/7    POS POS NEG   
180 5457/13 45 R UOQ 4X4X3 MUCINOUS   P A A A   3/4    POS POS NEG 0+0 
181 5882/13 60 L CQ 2X2X1 LOBULAR   A P A A 0         POS POS NEG 1+3 
182 6359/13 55 R CQ 5X4X3 METAPLASTIC   P A A A 0/5   NEG NEG NEG 3+4 
183 6884/13 50 R CQ 8X6X5 METAPLASTIC   P A A A 0/8   NEG NEG NEG 0+0 
184 7093/13 75 R UOQ 4X4X3 MUCINOUS   P A A A   3/11 FCD POS POS NEG 1+3 
185 7153/13 42 R UOQ 6X5X3 IDC NOS I P P A A   1/6  DCIS POS POS NEG   
186 7160/13 35 L UOQ 6X4X3 IDC NOS III P P P A   5/11 FCD NEG NEG NEG   
187 7173/13 60 L UOQ 6X5X4 IDC NOS I A A A A 0/6 FCD POS POS NEG 0+0 
188 7478/13 67 L UIQ 7X7X2 APOCRINE   A A A A 0/5 FCD NEG NEG NEG   
189 7750/13 42 L CQ 5X3X1 IDC NOS II A P A A   3/7  FA NEG NEG NEG   
190 8322/13 65 R UIQ 3X2X2 IDC NOS II P P P A   5/8  FCD POS POS NEG   
191 8329/13 59 R CQ 5X4X3 LOBULAR   A P A A 0/2 DCIS POS POS NEG 2+5 
192 8593/13 45 R CQ 2X2X2 IDC NOS III A A A A   4/7  FCD NEG NEG NEG   
193 8776/13 47 L CQ 4X3X2 IDC NOS II A P P A   1/8  FCD NEG NEG POS   
194 9073/13 67 R CQ 8X4X3 IDC NOS II A A P A 0       FCD POS POS NEG   
195 9156/13 40 R LOQ 3X2X2 IDC NOS I P A A A   1/4  FCD POS POS NEG   
196 9914/13 45 R CQ 3X3X3 IDC NOS II P P P A 0/3 DCIS POS POS POS   
197 10042/13 59 L LIQ 4X4X4 IDC NOS II P A A A   1/11   POS NEG POS   
198 10144/13 47 L CQ 5X2X1 IDC NOS III A A A A   4/5    POS POS NEG   
199 10417/13 38 R CQ 8X8X6 IDC NOS II A A A A 0       FA POS POS NEG   
200 10473/13 43 L CQ 6X5X4 IDC NOS II P P A A   2/3    POS POS POS   
201 10502/13 67 R LIQ 4X3X3 IDC NOS II A A P A   6/11 FCD NEG NEG NEG   
202 10658/13 35 R UIQ 2X1X1 IDC NOS II P P A  A   2/3  FCD NEG NEG POS   
203 10667/13 59 R LOQ 3X2X2 IDC NOS II A A P A   9/10   POS POS NEG   
204 10680/13 75 R CQ 1X1X1 IDC NOS I A P A A   5/7  ADH POS POS POS   
205 10885/13 53 L UOQ 2X2X1 IDC NOS II A P P A   8/9  FCD POS POS NEG   
206 10898/13 54 L UOQ 6X4X4 IDC NOS II P P A A   1/3  FCD NEG NEG NEG   
207 11034/13 49 R CQ 5X4X3 IDC NOS II A A A A   3/7  FA POS POS NEG   
208 11124/13 50 R UIQ 3X2X1 IDC NOS II P P A A   4/7  SA POS POS NEG   
209 11136/13 35 R UOQ 9X5X1 IDC NOS III A A P A   2/3    POS POS NEG   
210 11142/13 52 L CQ 4X3X1 IDC NOS II P P A A   5/9  FCD POS POS POS   
211 11234/13 51 L LOQ 2X2X2 IDC NOS I P P A A 0/6   NEG NEG NEG   
212 11294/13 47 R CQ 5X3X3 IDC NOS II A P P A   1/2  FCD NEG NEG NEG   
 
 KEY TO MASTER CHART 
 
R : Right 
L : Left 
TL : Tumor Location 
UOQ : Upper Outer Quadrant 
UIQ : Upper Inner Quadrant 
CQ : Central Quadrant 
LIQ : Lower Inner Quadrant 
LOQ : Lower Outer Quadrant 
HT : Histological Type 
IDC NOS : Infiltrating Ductal Carcinoma- Not Otherwise 
Specified 
PAPILLARY : Papillary Carcinoma 
MEDULLARY : Medullary Carcinoma 
METAPLASTIC : Metaplastic Carcinoma 
MUCINOUS : Mucinous Carcinoma 
APOCRINE : Apocrine Carcinoma 
LOBULAR : Lobular Carcinoma 
G : Grade 
AL : Associated Lesion 
DCIS : Ductal Carcinoma InSitu 
FCD : Fibrocystic Disease 
SA : Selerosing Adenosis 
UDH : Usual Ductal Hyperplasia 
ADH : Atypical Ductal Hyperplasia 
LVI : LymphoVascular Invasion 
LYI : Lymphocytic Infiltration 
N : Necrosis 
SK : Skin Involvement 
LN : Lymph Node Status 
ER : Estrogen Receptor 
PR : Progestrone Receptor 
AR : Androgen Receptor 
H2N : HER2neu 
A : Absent 
P : Present 
POS : Positive 
NOS : Negative 
 
